Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol

ABSTRACT

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

This application is a continuation-in-part of U.S. application Ser. No.08/985,492, filed Dec. 5, 1997, which claims the benefit of provisionalapplications under 35 U.S.C. §119(e), 60/032,254 and 60/032,783, both ofwhich were filed Dec. 6, 1996, the disclosures of which are incorporatedherein by reference in their entirety.

FIELD OF THE INVENTION

This invention relates to methods and compositions for increasing thelevel of high density lipoprotein (HDL) cholesterol and apolipoproteinAI in a patient and to methods and compositions for lowering the levelsof very low density lipoprotein (VLDL) cholesterol, and low densitylipoprotein (LDL) cholesterol in a patient. The invention includeswithin its scope methods and compositions which lower the expression of,or inhibit the activity of, a gene, LIPG, which encodes a lipase enzymethat lowers the levels of HDL cholesterol and apolipoprotein AI. Theinvention additionally includes within its scope methods andcompositions to increase the expression of, or enhance the activity of,the lipase enzyme, resulting in lower levels of VLDL and LDLcholesterol.

Lipids

Lipids are water-insoluble organic biomolecules, which are essentialcomponents of diverse biological functions, including the storage,transport, and metabolism of energy, and membrane structure andfluidity. Lipids are derived from two sources in man and other animals:some lipids are ingested as dietary fats and oils and other lipids arebiosynthesized by the human or animal. In mammals, at least 10% of thebody weight is lipid, the bulk of which is in the form oftriacylglycerols.

Triacylglycerols, also known as triglycerides and triacylglycerides, aremade up of three fatty acids esterified to glycerol. Dietarytriacylglycerols are stored in adipose tissues as a source of energy, orhydrolyzed in the digestive tract by triacylglycerol lipases, the mostimportant of which is pancreatic lipase. Triacylglycerols aretransported between tissues in the form of lipoproteins.

Lipoproteins are micelle-like assemblies found in plasma which containvarying proportions of different types of lipids and proteins (calledapoproteins). There are five main classes of plasma lipoproteins, themajor function of which is lipid transport. These classes are, in orderof increasing density: chylomicrons; very low density lipoproteins(VLDL); intermediate-density lipoproteins (IDL); low densitylipoproteins (LDL); and high density lipoproteins (HDL). Although manytypes of lipid are found associated with each lipoprotein class, eachclass transports predominantly one type of lipid: triacylglycerolsdescribed above are transported in chylomicrons, VLDL, and IDL; whereasphospholipids and cholesterol esters are transported in HDL and LDLrespectively.

Phospholipids are di-fatty acid esters of glycerol phosphate whichcontain a polar group coupled to the phosphate. Phospholipids areimportant structural components of cellular membranes. Phospholipids arehydrolyzed by enzymes called phospholipases. Phosphatidylcholine, anexemplary phospholipid, is a major component of most eukaryotic cellmembranes.

Cholesterol is the metabolic precursor of steroid hormones and bileacids as well as an essential constituent of cell membranes. In man andother animals, cholesterol is ingested in the diet and is synthesizedalso by the liver and other tissues. Dietary cholesterol is transportedfrom the intestine to the liver by large lipoprotein molecules in theblood. The liver secretes Very Low Density Lipoprotein (VLDL) whichtransports cholesterol and cholesterol ester and various other compoundsinto the bloodstream. VLDL is partially converted in adipose tissue toLow Density Lipoprotein (LDL). LDL transports both free and esterifiedcholesterol to body tissues. High Density Lipoprotein (HDL) transportscholesterol to the liver to be broken down and excreted.

Membranes surround every living cell and serve as a barrier between theintracellular and extracellular compartments. Membranes also enclose theeukaryotic nucleus, make up the endoplasmic reticulum, and servespecialized functions such as in the myelin sheath that surrounds axons.A typical membrane contains about 40% lipid and 60% protein, but thereis considerable variation. The major lipid components are phospholipids,specifically phosphatidylcholine and phosphatidylethanolamine, andcholesterol. The physicochemical properties of membranes, such asfluidity, can be changed by modification of either the fatty acidprofiles of the phospholipids or the cholesterol content. Modulating thecomposition and organization of membrane lipids also modulatesmembrane-dependent cellular functions, such as receptor activity,endocytosis, and cholesterol flux.

Enzymes

The triacylglycerol lipases are a family of enzymes which play severalpivotal roles in the metabolism of lipids in the body. Three members ofthe human triacylglycerol lipase family have been described: pancreaticlipase, lipoprotein lipase, and hepatic lipase (Goldberg, I. J., Le,N.-A., Ginsberg, H. N., Krauss, R. M., and Lindgren, F. T. (1988) J.Clin. Invest. 81, 561-568; Goldberg, I. J., Le, N., Paterniti J. R.,Ginsberg, H. N., Lindgren, F. T., and Brown, W. V. (1982) J. Clin.Invest. 70, 1184-1192; Hide, W. A., Chan, L., and Li, W.-H. (1992) J.Lipid. Res. 33, 167-178). Pancreatic lipase is primarily responsible forthe hydrolysis of dietary lipids. Variants of pancreatic lipase havebeen described, but their physiological role has not been determined(Giller, T., Buchwald, P., Blum-Kaelin, D., and Hunziker, W. (1992) J.Biol. Chem. 267, 16509-16516). Lipoprotein lipase is the major enzymeresponsible for the distribution and utilization of triglycerides in thebody. Lipoprotein lipase hydrolyzes triglycerides in both chylomicronsand VLDL. Hepatic lipase hydrolyzes triglycerides in IDL and HDL and isresponsible for lipoprotein remodeling. Hepatic lipase also functions asa phospholipase and hydrolyzes phospholipids in HDL.

Phospholipases play important roles in the catabolism and remodeling ofthe phospholipid component of lipoproteins and the phospholipids ofmembranes. Phospholipases also play a role in the release of arachidonicacid and the subsequent formation of prostaglandins, leukotrienes, andother lipids which are involved in a variety of inflammatory processes.

The aforementioned lipases are approximately. 450 amino acids in lengthand have leader signal peptides to facilitate secretion. The lipases arecomprised of two principal domains (Winkler, K., D'Arcy, A., andHunziker, W. (1990) Nature 343, 771-774). The amino terminal domaincontains the catalytic site while the carboxyl domain is believed to beresponsible for substrate binding, cofactor association, and interactionwith cell receptors (Wong, H., Davis, R. C., Nikazy, J., Seebart, K. E.,and Schotz, M. C. (1991) Proc. Natl. Acad. Sci. USA 88, 11290-11294; vanTilbeurgh, H., Roussel, A., Lalouel, J.-M., and Cambillau, C. (1994) J.Biol. Chem. 269, 4626-4633; Wong, H., Davis, R. C., Thuren, T., Goers,J. W., Nikazy, J., Waite, M., and Schotz, M. C. (1994) J. Biol. Chem.269, 10319-10323; Chappell, D. A., Inoue, I., Fry, G. L., Pladet, M. W.,Bowen, S. L., Iverius, P.-H., Lalouel, J.-M., and Strickland, D. K.(1994) J. Biol. Chem. 269, 18001-18006). The overall level of amino acidhomology between members of the family is 22-65%, with local regions ofhigh homology corresponding to structural homologies which are linked toenzymatic function.

The naturally occurring lipoprotein lipase is glycosylated.Glycosylation is necessary for LPL enzymatic activity (Semenkovich, C.F., Luo, C.-C., Nakanishi, M. K., Chen, S.-H., Smith, L. C., and Chan L.(1990) J. Biol. Chem. 265, 5429-5433). There are two sites for N-linkedglycosylation in hepatic and lipoprotein lipase and one in pancreaticlipase. Additionally, four sets of cysteines form disulfide bridgeswhich are essential in maintaining structural integrity for enzymaticactivity (Lo, Smith, L. C., and Chan, L. (1995) Biochem. Biophys. Res.Commun. 206, 266-271; Brady, L., Brzozowski, A. M., Derewenda, Z. S.,Dodson, E., Dodson G., Tolley, S., Turkenburg, J. P., Christiansen, L.,Huge-Jensen B., Norskov, L., Thim, L., and Menge, U. (1990) Nature 343,767-770).

Members of the triacylglycerol lipase family share a number of conservedstructural features. One such feature is the “GXSXG” motif, in which thecentral serine residue is one of the three residues comprising the“catalytic triad” (Winkler, K., D'Arcy, A., and Hunziker, W. (1990)Nature 343, 771-774; Faustinella, F., Smith, L. C., and Chan, L. (1992)Biochemistry 31, 7219-7223). Conserved aspartate and histidine residuesmake up the balance of the catalytic triad. A short span of 19-23 aminoacids (the “lid region”) forms an amphipathic helix structure and coversthe catalytic pocket of the enzyme (Winkler, K., D'Arcy, A., andHunziker, W. (1990) Nature 343, 771-774). This region divergessignificantly between members of the family. It has been determinedrecently that the span confers, substrate specificity to the enzymes(Dugi, K. A., Dichek H. L., and Santamarina-Fojo, S. (1995) J. Biol.Chem. 270, 25396-25401). Comparisons between hepatic and lipoproteinlipase have demonstrated that differences in triacylglycerol lipase andphospholipase activities of the enzymes are in part mediated by this lidregion (Dugi, K. A., Dichek H. L., and Santamarina-Fojo, S. (1995) J.Biol. Chem. 270, 25396-25401).

The triacylglycerol lipases possess varying degrees of heparin bindingactivity. Lipoprotein lipase has the highest affinity for heparin. Thisbinding activity has been mapped to stretches of positively chargedresidues in the amino terminal domain (Ma, Y., Henderson, H. E., Liu,M.-S., Zhang, H., Forsythe, I. J., Clarke-Lewis, I., Hayden, M. R., andBrunzell, J. D. J. Lipid Res. 35, 2049-2059). The localization oflipoprotein lipase to the endothelial surface (Cheng, C. F., Oosta, G.M., Bensadoun, A., and Rosenberg, R. D. (1981) J. Biol. Chem. 256,12893-12896) is mediated primarily through binding to surfaceproteoglycans (Shimada K., Gill, P. J., Silbert, J. E., Douglas, W. H.J., and Fanburg, B. L. (1981) J. Clin. Invest. 68, 995-1002; Saxena, U.,Klein, M. G., and Goldberg, I. J. (1991) J. Biol. Chem. 266,17516-17521; Eisenberg, S., Sehayek, E., Olivecrona, T., and Vlodaysky,I. (1992) J. Clin Invest. 90, 2013-2021). It is this binding activitywhich allows the enzyme to accelerate LDL uptake by acting as a bridgebetween LDL and the cell surface (Mulder, M., Lombardi, P., Jansen, H.,vanBerkel T. J., Frants R. R., and Havekes, L. M. (1992) Biochem.Biophys. Res. Comm. 185, 582-587; Rutledge, J. C., and Goldberg, I. J.,(1994) J. Lipid Res. 35. 1152-1160; Tsuchiya, S., Yamabe, M., Yamaguchi,T., Kobayashi, Y., Konno, T., and Tada, K. (1980) Int. J. Cancer 26,171-176).

Lipoprotein lipase and pancreatic lipase are both known to function inconjunction with co-activator proteins: apolipoprotein CII forlipoprotein lipase; and colipase for pancreatic lipase.

The genetic sequences encoding human pancreatic lipase, hepatic lipaseand lipoprotein lipase have been reported (Genbank accession #M93285,#303540, and #M15856 respectively). The messenger RNAs of human hepaticlipase and pancreatic lipase are approximately 1.7 and 1.8 kilobases inlength respectively. Two mRNA transcripts of 3.6 and 3.2 kilobases areproduced from the human lipoprotein lipase gene. These two transcriptsutilize alternate polyadenylation signals and differ in theirtranslational efficiency (Ranganathan, G., Ong, J. M., Yukht, A.,Saghizadeh, M., Simsolo, R. B., Pauer, A., and Kern, P. A. (1995) J.Biol. Chem. 270, 7149-7155).

Physiological Processes

The metabolism of lipids involves the interaction of lipids,apoproteins, lipoproteins, and enzymes.

Hepatic lipase and lipoprotein lipase are multifunctional proteins whichmediate the binding, uptake, catabolism, and remodeling of lipoproteinsand phospholipids. Lipoprotein lipase and hepatic lipase function whilebound to the luminal surface of endothelial cells in peripheral tissuesand the liver respectively. Both enzymes participate in reversecholesterol transport, which is the movement of cholesterol fromperipheral tissues to the liver either for excretion from the body orfor recycling. Genetic defects in both hepatic lipase and lipoproteinlipase are known to be the cause of familial disorders of lipoproteinmetabolism. Defects in the metabolism of lipoproteins result in seriousmetabolic disorders, including hypercholesterolemia, hyperlipidemia, andatherosclerosis.

Reported Developments

Atherosclerosis is a complex, polygenic disease which is defined inhistological terms by deposits (lipid or fibrolipid plaques) of lipidsand of other blood derivatives in blood vessel walls, especially thelarge arteries (aorta, coronary arteries, carotid). These plaques, whichare more or less calcified according to the degree of progression of theatherosclerotic process, may be coupled with lesions and are associatedwith the accumulation in the vessels of fatty deposits consistingessentially of cholesterol esters. These plaques are accompanied by athickening of the vessel wall, hypertrophy of the smooth muscle,appearance of foam cells (lipid-laden cells resulting from uncontrolleduptake of cholesterol by recruited macrophages) and accumulation offibrous tissue. The atheromatous plaque protrudes markedly from thewall, endowing it with a stenosing character responsible for vascularocclusions by atheroma, thrombosis or embolism, which occur in thosepatients who are most affected. These lesions can lead to seriouscardiovascular pathologies such as infarction, sudden death, cardiacinsufficiency, and stroke.

High Density Lipoprotein (HDL) Cholesterol Levels and AtheroscleroticDiseases

High density lipoprotein (HDL) cholesterol levels are inverselyassociated with risk of atherosclerotic cardiovascular disease (Gordonet al., N. Engl. J. Med., 321, 1311-1316 (1989)). At least 50% of thevariation in HDL cholesterol levels is genetically determined (Breslow,J. L., The Metabolic Basis of Inhereited Disease, 2031-2052,McGraw-Hill, New York (1995); Heller et al., N. Engl. J. Med., 328,1150-1156 (1993)), but the genes responsible for variation in HDL levelshave not been fully elucidated. Lipoprotein lipase (LPL) and hepaticlipase (HL), two members of the triacylglycerol (TG) lipase family, bothinfluence HDL metabolism (Breslow, supra; Murthy et al., Pharmacol.Ther., 70, 101-135 (1996); Goldberg, J. I., J. Lipid Res., 37, 693-707(1996); Bensadoun et al., Curr. Opin. Lipidol., 7, 77-81 (1996)) and theHL (LIPC) locus has been associated with variation in HDL cholesterollevels in humans (Cohen et al., J. Clin. Invest., 94, 2377-2384 (1994);Guerra et al., Proc. Natl. Acad. Sci. USA, 94, 4532-4537 (1997)). Thenormal range for HDL cholesterol is about 35 to 65 mg/dL, and the HDLlevel should account for more than 25% of the total cholesterol.

Very Low Density Lipoprotein (VLDL) and Low Density Lipoprotein (LDL)Cholesterol Levels and Atherosclerotic Diseases

High levels of circulating LDL and VLDL cholesterol are associated withincreased risk of atherosclerosis.

VLDL are the precursors of LDL. Therapeutic agents that lower plasmaVLDL and LDL cholesterol levels are highly desirable because of theknown strong association between these lipid parameters and coronaryheart disease.

Epidemiologic studies have demonstrated a strong relationship betweenelevated LDL cholesterol and coronary heart disease (CHD) and otheratherosclerotic vascular diseases (Kannell, W. B., Am. J. Cardiol., 76,69C-77C (1995)). Three major secondary prevention trials performed withstatins have demonstrated that reduction of LDL cholesterol levelsresult in significant reduction in CHD events and total mortality(Scandinavian Simvastatin Survival Study Group, Lancet, 344, 1383-1389(1994); Sacks et al., N. Engl. J. Med., 335, 1001-1009 (1996); Tonkin etal., N. Engl. J. Med., 339, 1349-1357 (1998); Grundy, S. M., Editorial,1436-1439 (1998)). Two large primary prevention trials with statins havealso demonstrated significant benefit of LDL cholesterol reduction withstatins in reducing cardiovascular events (Grundy, supra; Shepherd etal., N. Engl. J. Med., 333, 1301-1307 (1995); Downs et al., JAMA, 279,1615-1622 (1998)). However, current therapies do not adequately reduceLDL cholesterol levels in all persons. VLDL cholesterol levels have alsobeen recognized to be associated with increased risk of CHD (Kannel,supra). Current therapies do not have as much effect in reducing VLDLcholesterol as LDL cholesterol. Therefore, new approaches to reducingboth LDL cholesterol and VLDL cholesterol are still needed.

Ideally, the range for VLDL cholesterol is about 1 to 30 mg/dL and therange for LDL cholesterol is about 60 to 160 mg/dL. The LDL to HDL ratiois ideally less than 3.5.

The Role of Triacylglycerol Lipases in Atherosclerotic Diseases

The role of triacylglycerol lipases in vascular pathologies such asatherosclerosis has been an area of intense study (reviewed inOlivecrona, G., and Olivecrona, T. (1995) Curr. Opin. Lipid. 6,291-305). Generally, the action of the lipoprotein lipase is believed tobe antiatherogenic because this enzyme lowers serum triacylglycerollevels and promote HDL formation. Transgenic animals expressing humanlipoprotein lipase have decreased levels of plasma triglycerides and anincreased level of high density lipoprotein (HDL) (Shimada, M., Shimano,H., Gotoda, T., Yamamoto, K., Kawamura, M., Inaba, T., Yazaki, t., andYamada, N. (1993) J. Biol. Chem. 268, 17924-17929; Liu, M.-S., Jirik, F.R., LeBoeuf, R. C., Henderson, H., Castellani, L. W., Lusis, A. J., ma,Y., Forsythe, Zhang, H., Kirk, E., Brunzell, J. D., and Hayden, M. R.(1994) J. Biol. Chem. 269, 11417-11424). Humans with genetic defectsresulting in decreased levels of lipoprotein lipase activity have beenfound to have hypertriglyceridemia, but no increased risk of coronaryheart disease. This is reported to be due to the lack of production ofintermediate-sized, atherogenic lipoproteins which could accumulatewithin the subendothelial space (Zilversmit, D. B. (1973) Circ. Res. 33,633-638).

In contrast to lipoprotein lipase (LPL), the physiologic function of HLappears to be related to the metabolism of lipoprotein remnants and HDL(Bensadoun et al., Curr. Opin. Lipidol., 7, 77-81 (1996)). Geneticdeficiency of HL is associated with modestly increased levels ofremnants and HDL cholesterol in humans (Hegele et al., Arterioscler.Thrombi., 13, 720-728 (1993)) and mutant mice (Homanics et al., J. Biol.Chem., 270, 2974-2980 (1995)). Despite increased plasma cholesterollevels, HL deficiency is associated with reduced atherosclerosis in apoEmutant mice (Mezdour et al., J. Biol. Chem., 272, 13570-13575 (1997)).Transgenic animals overexpressing HL have decreased HDL (Busch et al.,J. Biol. Chem., 269, 16376-16382 (1994); Fan et al., Proc. Natl. Acad.Sci. USA, 91, 8724-8728 (1994)). Increased HL activity in humans isassociated with low HDL cholesterol. The HL locus on chromosome 15q21has been associated with variation in plasma HDL cholesterol levels inhumans (Cohen et al., J. Clin. Invest., 94, 2377-2384 (1994); Guerra etal., Proc. Natl. Acad. Sci. USA, 94 4532-4537 (1997)), but accounts foronly a portion of the genetic contribution to variation in HDLcholesterol levels. There is at least one major locus influencing HDLcholesterol levels in humans that is distinct from the HL locus (Mahaneyet al., Arterioscler. Thromb. Vasc. Biol., 15, 1730-1739 (1995)).

In the localized area of an atherosclerotic lesion, the increased levelof lipase activity is hypothesized to accelerate the atherogenic process(Zilversmit, D. B. (1995) Clin. Chem. 41, 153-158; Zambon, A., Torres,A., Bijvoet, S., Gagne, C., Moojani, S., Lupien, P. J., Hayden M. R.,and Brunzell, J. D. (1993) Lancet 341, 1119-1121). This may be due to anincrease in the binding and uptake of lipoproteins by vascular tissuemediated by lipases (Eisenberg, S., Sehayek, E., Olivecrona, T.Vlodaysky, I. (1992) J. Clin. Invest. 90, 2013-2021; Tabas, I., Li, I.,Brocia R. W., Xu, S. W., Swenson T. L. Williams, K. J. (1993) J. Biol.Chem. 268, 20419-20432; Nordestgaard, B. G., and Nielsen, A. G. (1994)Curr. Opin. Lipid, 5, 252-257; Williams, K. J., and Tabas, I. (1995)Art. Thromb. and Vasc. Biol. 15, 551-561). Additionally, a high locallevel of lipase activity may result in cytotoxic levels of fatty acidsand lysophosphatidylcholine being produced in precursors ofatherosclerotic lesions.

Despite the understanding that has evolved regarding the role of lipaseenzyme activity in regulating the levels of lipids and the variousplasma lipoproteins, there is a need to identify and develop therapieswhich can increase the levels of HDL cholesterol, as well as lower thelevels of VLDL and LDL cholesterol to reduce the risk of developingatherosclerotic cardiovascular diseases.

SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided acomposition for lowering the expression of the LIPG gene in a patientcomprising an antisense nucleic acid, including for example, anexpression vector which includes said antisense nucleic acid. Examplesof preferred expression vectors are retroviral vectors, adenoviralvectors, adeno-associated viral vectors, herpesviral vectors, and nakedDNA vectors. The antisense nucleic acid can be, for example, anoligonucleotide which contains chemically modified bases.

Another aspect of the present invention is the provision of acomposition for lowering the enzymatic activity of the LIPG polypeptidein a patient comprising a neutralizing antibody capable of binding tothe LIPG polypeptide and lowering its enzymatic activity, including, forexample, an expression vector which includes a DNA sequence encodingsaid antibody. Examples of preferred expression vectors are retroviralvectors, adenoviral vectors, adeno-associated viral vectors, herpesviralvectors, and naked DNA vectors.

Still another aspect of the present invention is the provision of acomposition for lowering the enzymatic activity of the LIPG polypeptidein a patient comprising an intracellular binding protein, including, forexample, an expression vector which includes a DNA sequence encodingsaid intracellular binding protein. Examples of preferred expressionvectors are retroviral vectors, adenoviral vectors, adeno-associatedviral vectors, herpesviral vectors, and naked DNA vectors.

Yet other aspects of the present invention are the provision of: (A) acomposition which comprises an inhibitor that is capable of inhibitingthe enzymatic activity of the LIPG polypeptide in a patient; (B) acomposition which comprises an inhibitor that is capable of lowering theexpression of the LIPG gene in a patient; and (C) composition which iscapable of lowering the expression of LIPG in a patient and whichcomprises a ribozyme, including, for example, an expression vector whichincludes a DNA sequence encoding said ribozyme. Examples of preferredexpression vectors are retroviral vectors, adenoviral vectors,adeno-associated viral vectors, herpesviral vectors, and naked DNAvectors. A preferred ribozyme is a hammerhead ribozyme.

The present invention provides also: (D) a composition which increasesthe level of LIPG polypeptide in a patient and which comprises anexpression vector that includes a DNA sequence encoding the LIPGpolypeptide or an enhancer that is capable of increasing the expressionof the LIPG gene; and (E) a composition which increases the enzymaticactivity of LIPG polypeptide in a patient which comprises an enhancerthat binds to and enhances the enzymatic activity of the LIPGpolypeptide.

In addition, the present invention provides a method for raising thelevel of high density lipoprotein (HDL) cholesterol and apolipoproteinAI in a patient by administering to the patient a composition whichlowers the enzymatic activity of LIPG in said patient, for example, bylowering the level of LIPG polypeptide in the patient. In preferredform, the method involves the use of a composition which comprises anantisense nucleic acid, particularly one that is modified to increasethe chemical stability of the nucleic acid. The aforementioned methodcan be practiced also by use of a composition which comprises aneutralizing antibody capable of binding to the LIPG polypeptide andlowering its enzymatic activity or a composition which comprises aninhibitor which inhibits the enzymatic activity of LIPG polypeptide, forexample, a compound which lowers the expression of the LIPG gene or acomposition which comprises a ribozyme that cleaves mRNA encoding LIPG,or a composition which comprises a DNA molecule and a liposome, forexample, a cationic liposome.

In preferred form, the aforementioned method comprises also theadministration of a composition which is capable of expressingapolipoprotein AI in said patient.

Another aspect of the present invention is the provision of a method forlowering the level of very low density lipoprotein (VLDL) cholesterol ina patient by administering to the patient a composition which is capableof increasing the enzymatic activity of LIPG in said patient, forexample, by use of a composition which comprises an LIPG polypeptide anda pharmaceutically acceptable carrier and which includes preferably anexpression vector that is capable of expressing an LIPG polypeptide,preferably a retroviral vector, an adenoviral vector, or anadeno-associated viral vector. The aforementioned method can bepracticed by use of a composition which comprises an enhancer thatenhances the enzymatic activity of LIPG polypeptide or an enhancer thatincreases expression of the LIPG gene.

Still another aspect of the present invention is the provision of amethod for lowering the level of low density lipoprotein (LDL)cholesterol in a patient by administering to the patient a compositionwhich is capable of increasing the enzymatic activity of LIPG in thepatient, preferably by use of an LIPG polypeptide, for example, by useof an expression vector that is capable of expressing the LIPGpolypeptide, preferably by use of a retroviral vector, an adenoviralvector, or an adeno-associated viral vector. The aforementioned methodincludes preferably the use of a composition which comprises an enhancerthat enhances the enzymatic activity of LIPG polypeptide or an enhancerwhich increases the expression of the LIPG gene.

The present invention provides also a method for lowering the level ofLDL cholesterol in a patient by administering to the patient an enhancerwhich preferentially enhances the enzymatic reactions between LIPGpolypeptide and LDL cholesterol relative to the enzymatic reactionsbetween LIPG polypeptide and HDL cholesterol and apolipoprotein AI.

In addition, the present invention provides a method for lowering thelevel of VLDL cholesterol in a patient by administering to the patientan enhancer which preferentially enhances the enzymatic reactionsbetween LIPG polypeptide and VLDL cholesterol relative to the enzymaticreactions between LIPG polypeptide and HDL cholesterol andapolipoprotein AI.

Still another aspect of the present invention is the provision of amethod for diagnosing a predisposition to low HDL cholesterol andapolipoprotein AI levels by obtaining a tissue sample from a patient andmeasuring the level of LIPG polypeptide in the sample, for example, byuse of blood tissue and the use of an immunoassay for measurement. Inanother aspect of the present invention, the levels of LIPG polypeptideare measured by measuring the levels of LIPG mRNA.

An additional aspect of the present invention is the provision of amethod for determining whether a test compound can inhibit the enzymaticreaction between the LIPG polypeptide and HDL cholesterol andapolipoprotein AI comprising: (A) comparing the level of HDL cholesteroland apolipoprotein AI in a first sample comprising: (1) HDL cholesteroland apolipoprotein AI, (2) LIPG polypeptide, and (3) the test compoundwith the level of HDL cholesterol and apolipoprotein AI in anothersample comprising: (4) HDL cholesterol and apolipoprotein AI, and (5)LIPG polypeptide; and (B) identifying whether or not the test compoundis effective in inhibiting the enzymatic reaction between the LIPGpolypeptide and HDL cholesterol and apolipoprotein AI by observingwhether or not the first sample has a higher level of HDL cholesteroland apolipoprotein AI than that of said other sample.

The present invention provides also a method for determining whether atest compound can enhance the enzymatic reaction between the LIPGpolypeptide and VLDL cholesterol comprising: (A) comparing the level ofVLDL cholesterol in a first sample comprising: (1) VLDL cholesterol, (2)LIPG polypeptide, and (3) the test compound with the level of VLDLcholesterol in another sample comprising: (4) VLDL cholesterol, and (5)LIPG polypeptide; and (B) identifying whether or not the test compoundis effective in enhancing the enzymatic reaction between the LIPGpolypeptide and VLDL cholesterol by observing whether or not the firstsample has a lower level of VLDL cholesterol than that of said othersample.

Still another aspect of the present invention is the provision of amethod for determining whether a test compound can enhance the enzymaticreaction between the LIPG polypeptide and LDL cholesterol comprising:(A) comparing the level of LDL cholesterol in a first sample comprising:(1) LDL cholesterol, (2) LIPG polypeptide, and (3) the test compoundwith the level of LDL cholesterol in another sample comprising: (4) LDLcholesterol, and (5) LIPG polypeptide; and (B) identifying whether ornot the test compound is effective in enhancing the enzymatic reactionbetween the LIPG polypeptide and LDL cholesterol by observing whether ornot the first sample has a lower level of LDL cholesterol than that ofsaid other sample.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the sequences (SEQ ID Nos: 17-31) of the primers used inthe exemplified PCR amplifications.

FIG. 2 shows the nucleic acid sequence (SEQ ID NO: 1) and the deducedamino acid sequence (SEQ ID NO: 2) of the differential display RT-PCRproduct containing the LIPG gene cDNA. The sequences corresponding tothe two primers used in the amplification are underlined. Thetermination codon and polyadenylation signal are boxed. The GAATTCmotifs and flanking sequence are from the pCRII vector into which theproduct was cloned.

FIG. 3 shows the nucleic acid sequence (SEQ ID NO: 3) and the deducedamino acid sequence (SEQ ID NO: 4) of the 5′RACE extension of the LIPGcDNA. The sequences corresponding to the two primers used in theamplification are underlined. The GAATTC motifs and flanking sequenceare from the pCRII vector into which the product was cloned.

FIG. 4 shows the sequence (SEQ ID NO: 7) of the cDNA containing thecomplete open reading frame of the LIPG gene, LLGXL. The start codon(ATG) and termination codon (TGA) are boxed. The DraI site (TTTAAA) andSrfI site (GCCCGGGC) used in the construction of the expression vectorsare underlined.

FIG. 5 shows the deduced amino acid sequence (SEQ ID NO: 8) of the LLGXLprotein. The predicted signal sequence is underlined.

FIG. 6 shows a protein sequence alignment of the members of thetriacylglycerol lipase gene family (SEQ ID Nos: 13-15). Shaded residuesare identical to the LLGXL protein (SEQ ID, NO: 8). The deduced aminoacid sequence of human LIPG(EL) is provided-on the top line and iscompared with the other major members of the TG lipase family, LPL, HLand PL. EL residues identical to those in at least one other member ofthe family are shaded as well as the corresponding residue in the otherfamily member. Amino acids are numbered according to conventionbeginning with the initial residue of the secreted protein. Thepredicted sites of signal peptide cleavage are marked with a solid linebetween amino acid residues. The GXSXG lipase motif containing theactive serine is boxed. The amino acids of the catalytic triad aremarked with an asterisk. The conserved cysteines are marked with filledcircles. Potential N-linked glycosylation sites are marked witharrowheads. The lid region is indicated by a bold line. Gaps wereintroduced into the sequences to maximize the alignment values using theCLUSTAL program.

FIG. 7 shows a northern analysis of LIPG mRNA in THP-1 cells. Cells werestimulated with either PMA or PMA and oxidized LDL (PMA+oxLDL). Numbersat the left indicate the positions of RNA standards (in kilobases).

FIG. 8 shows a northern-blot analysis of expression of LIPG mRNAcompared with LPL in human tissues. A blot containing mRNA from theindicated human tissues was incubated with radiolabelled LPL and β-actin(ACTB) probes as described.

FIG. 9 shows a Northern-blot analysis of cultured cell lines. The panelon the left (lanes 1-6) was hybridized with the LIPG(EL) probe and thaton the right (lanes 7-12) with the LPL probe. Lanes 1, 7, unstimulatedHUVEC; lanes 2, 8, HUVEC stimulated with PMA; lanes 3, 9, HUVECstimulated with thrombin; lanes 4, 10, unstimulated HCAEC; lanes 5, 11,HCAEC stimulated with PMA; lanes 6, 12, THP-1 stimulated with PMA.

FIG. 10 shows the sequence of the immunizing peptide (SEQ ID NO: 16) andits relation to the LLGXL protein sequence. The peptide is shown in theshaded box. The terminal cysteine was introduced to aid coupling of thepeptide to the carrier protein.

FIG. 11 shows the results obtained when conditioned media from HUVEC andHCAEC were subjected to immunoblot analysis with rabbit anti-EL peptideantiserum. Lane 1, unconditioned media; lane 2, unstimulated HUVEC; lane3, HUVEC stimulated with PMA; lane 4, unstimulated HCAEC; lane 5, HCAECstimulated with PMA.

FIG. 12 shows a western analysis of heparin-Sepharose bound proteins inconditioned medium from COS-7 cells transiently transfected with anexpression vector containing a cDNA for LLGN or LLGXL or no DNA (Mock).Proteins from PMA-stimulated endothelial cells (HCAEC+PMA) were includedfor size reference. Numbers to the left indicate the apparent molecularweight of the major immunoreactive proteins as determined by acomparison to protein standards.

FIG. 13 shows the sequence of the rabbit LIPG PCR product (RLLG. SEQ,SEQ ID NO: 12) and the sequence alignment between the rabbit LIPG PCRproduct and the corresponding sequence in the human cDNA (LLG7742A).Identical nucleotides are shaded.

FIG. 14 shows the phospholipase A activity of human EL-AS, EL and LPLusing a phosphatidylcholine substrate. To perform the assay 700 μl ofconditioned medium harvested from COS-7 cells transiently transfectedwith either pcDNA3.0/LIPG-AS, LIPG, or LPL expression constructs wereassayed in triplicate for phospholipase activities as described below.Following a two hour incubation at 37° C., reactions were terminated,and 14C labeled free fatty-acid was extracted, and counted to determinethe amount of free fatty-acid produced.

FIG. 15 shows the triacylglyceride lipase activity of human EL-AS, ELand LPL using a triolein substrate. To perform the assay 700 μl ofconditioned medium harvested from COS-7 cells transiently transfectedwith either pcDNA3.0/LIPG-AS, LIPG, or LPL expression constructs wasassayed in triplicate for triglyceride activities described below.Following a two hour incubation at 37° C., reactions were terminated,and 14C labeled free fatty-acid was extracted, and counted to determinethe amount of free fatty-acid produced.

FIG. 16 shows the hybridization of LIPG and LPL probes to genomic DNAsfrom different species.

FIG. 17 shows expression of LIPG in the liver of a wild-type mouse 5days after AdhEL injection. Lane 1, liver from mouse injected withAdnull; lane 2, liver from mouse injected with AdhEL.

FIG. 18 shows plasma levels of HDL cholesterol in AdhEL- andAdnull-injected wild-type mice.

FIG. 19 shows lipoprotein profiles in wild-type mice injected with AdhELand Adnull at baseline before injection (left) and 14 days afterinjection (right).

FIG. 20 shows HDL cholesterol levels in human apoA-I transgenic miceafter injection with Adnull or AdhEL.

FIG. 21 shows ApoA-I levels in human apoA-1 transgenic mice afterinjection with Adnull or AdhEL.

FIG. 22 shows the effect of injection of AdhEL in LDL receptor-deficientmice on VLDL/LDL cholesterol levels.

FIG. 23 shows the effect of AdhEL on HDL receptor-deficient mice on HDLcholesterol levels.

DETAILED DESCRIPTION OF THE INVENTION

The detailed description which follows sets forth the basis for thepresent invention, followed by a definitions section. Following thedefinitions section, the various compositions useful in the practice ofthe invention are discussed, followed by a discussion of the methodsused to lower or raise the levels of LIPG activity.

The Enzymatic Activity of the LIPG Gene Product

The present invention relates to methods for regulating the levels ofHDL cholesterol and apolipoprotein AI, VLDL cholesterol and LDLcholesterol utilizing methods and compositions which lower or raise theactivity of the LIPG lipase enzyme. In particular, the present inventionis based in part on the discovery of the enzymatic activity of thepolypeptide products of the LIPG gene on HDL cholesterol andapolipoprotein AI, VLDL cholesterol and LDL cholesterol. The polypeptideproducts of LIPG are members of the triacylglycerol lipase family andcomprise an approximately 39 kD catalytic domain of the triacylglycerollipase family, e,g., having the sequence SEQ ID NO: 10. Because thisnewly discovered lipase was found to be synthesized by endothelial cellsand this is a unique feature compared with other members of thetriacylglycerol lipase family, this lipase has been named “endotheliallipase” (EL). Because the LIPG gene will be discussed extensively in thesections which follow, EL will be hereinafter referred to as LIPGpolypeptide, for the purposes of clarity. In general, the LIPGpolypeptide is found in two major forms, referred to hereinafter as “theLLGN polypeptide” and “the LLGXL polypeptide.” The LLGN polypeptide, has354 amino acids. The LLGXL polypeptide has 500 amino acids and exhibits43% similarity to human lipoprotein lipase and 37% similarity to humanhepatic lipase. As used herein, the term “LIPG polypeptide” or “LIPGprotein” encompasses both LLGN and LLGXL.

The sequence of the LIPG polypeptide contains the characteristic GXSXGlipase motif, a conserved catalytic triad, a 19-residue lid region,conserved heparin and lipoprotein binding sites and 5 potential N-linkedglycosylation sites. The region with the greatest sequence divergence inthe triacylglycerol lipase family is the lid domain, which forms anamphipathic helix covering the catalytic pocket of the enzyme (Winkleret al., Nature, 343, 771-774 (1990); van Tilbeurgh et al., J. Biol.Chem., 269, 4626-4633 (1994)) and confers substrate specificity to theenzymes of this family (Dugi et al., J. Biol. Chem., 270, 25396-25401(1995)). The 19-residue lid region of LIPG is three residues shorter andless amphipathic than those found in lipoprotein lipase and hepaticlipase, consistent with a different enzymatic profile. The predictedmolecule weight of the mature protein is approximately 55 kD; a 68 kDform is likely to be a glycosylated form, whereas a 40 kD form may bethe product of a specific proteolytic cleavage.

The LIPG polypeptide has the ability to lower the levels of HDLcholesterol and apolipoprotein AI as well as the levels of VLDLcholesterol and LDL cholesterol. It is well established that lowered HDLcholesterol levels result in increased susceptibility to atherosclerosisand increased levels of HDL cholesterol can dramatically reducesusceptibility to atherosclerosis.

One physiologic role of LIPG may be to hydrolyse HDL phospholipid inperipheral tissues and in liver to facilitate selective uptake of HDLcholesteryl ester via the HDL receptor SR-BI (Kozarsky et al., Nature,387, 414-417 (1997)). Another possible role is the facilitation ofapoB-containing remnant lipoprotein uptake, similar to the role ofhepatic lipase (Mahley et al., J. Lipid Res., 40, 1-16 (1999)). Inaddition, LIPG is abundantly expressed in the placenta, and a role forthis enzyme in development is possible, given the importance of lipidtransport in fetal development (Farese et al., Trends Genet., 14,115-120 (1998)).

Based on HDL cholesterol's beneficial properties, it is desirable toraise HDL cholesterol levels by lowering the enzymatic activity of LIPG.Accordingly, the present invention is directed to methods andcompositions which lower the activity of LIPG in the body by loweringthe expression of the LIPG gene or lowering the enzymatic activity ofthe LIPG polypeptide.

Given the ability of the LIPG polypeptide to reduce the levels of VLDLcholesterol and LDL cholesterol and the studies demonstrating thecorrelation between high levels of these compounds and atheroscleroticdiseases, it is desirable to lower the level of these compounds in apatient. Accordingly, the present invention additionally providesmethods and compositions for increasing the expression of the LIPG geneand increasing the enzymatic activity of the LIPG polypeptides.

There are set forth hereafter definitions of terms used herein anddescriptions of preferred embodiments of the present invention.

DEFINITIONS

The following defined terms are used throughout the presentspecification and should be helpful in understanding the scope andpractice of the present invention.

A “polypeptide” is a polymeric compound comprised of covalently linkedamino acid residues. Amino acids are classified into seven groups on thebasis of the side chain: (1) aliphatic side chains, (2) side chainscontaining a hydroxylic (OH) group, (3) side chains containing sulfuratoms, (4) side chains containing an acidic or amide group, (5) sidechains containing a basic group, (6) side chains containing an aromaticring, and (7) proline, an imino acid in which the side chain is fused tothe amino group.

A “protein” is a polypeptide which plays a structural or functional rolein a living cell.

The polypeptides and proteins of the invention may be glycosylated orunglycosylated.

“Homology” means similarity of sequence reflecting a common evolutionaryorigin. Polypeptides or proteins are said to have homology, orsimilarity, if a substantial number of their amino acids are either (1)identical, or (2) have a chemically similar side chain. Nucleic acidsare said to have homology if a substantial number of their nucleotidesare identical.

“Isolated polypeptide” or “isolated protein” is a polypeptide or proteinwhich is substantially free of those compounds that are normallyassociated therewith in its natural state (e.g., other proteins orpolypeptides, nucleic acids, carbohydrates, lipids). “Isolated” is notmeant to exclude artificial or synthetic mixtures with other compounds,or the presence of impurities which do not interfere with biologicalactivity, and which may be present, for example, due to incompletepurification, addition of stabilizers, or compounding into apharmaceutically acceptable preparation.

A molecule is “antigenic” when it is capable of specifically interactingwith an antigen recognition molecule of the immune system, such as animmunoglobulin (antibody) or T cell antigen receptor. An antigenicpolypeptide contains at least about 5, and preferably at least about 10,amino acids. An antigenic portion of a molecule can be that portion thatis immunodominant for antibody or T cell receptor recognition, or it canbe a portion used to generate an antibody to the molecule by conjugatingthe antigenic portion to a carrier molecule for immunization. A moleculethat is antigenic need not be itself immunogenic, i.e., capable ofeliciting an immune response without a carrier.

“LLGN polypeptide” and “LLGN protein” mean a polypeptide including thesequence SEQ ID NO: 6, said polypeptide being glycosylated ornon-glycosylated.

“LLGXL polypeptide” and “LLGXL protein” mean a polypeptide including thesequence SEQ ID NO: 8, said polypeptide being glycosylated ornon-glycosylated.

“LIPG polypeptide” and “LIPG protein” describe the lipase enzyme encodedby the LIPG gene and generically describes both the LLGN polypeptide andthe LLGXL polypeptide.

“Endothelial lipase,” or “EL”, refer to the lipase enzyme encoded by theLIPG gene and is equivalent to the term LIPG polypeptide.

The LIPG polypeptide or protein of the invention includes any analogue,fragment, derivative, or mutant which is derived from an LIPGpolypeptide and which retains at least one biological property of theLIPG polypeptide. Different variants of the LIPG polypeptide exist innature. These variants may be allelic variations characterized bydifferences in the nucleotide sequences of the structural gene codingfor the protein, or may involve differential splicing orpost-translational modification. The skilled artisan can producevariants having single or multiple amino acid substitutions, deletions,additions, or replacements. These variants may include, inter alia: (a)variants in which one or more amino acid residues are substituted withconservative or non-conservative amino acids, (b) variants in which oneor more amino acids are added to the LIPG polypeptide, (c) variants inwhich one or more of the amino acids includes a substituent group, and(d) variants in which the LIPG polypeptide is fused with anotherpolypeptide such as serum albumin. Other LIPG polypeptides of theinvention include variants in which amino acid residues from one speciesare substituted for the corresponding residue in another species, eitherat conserved or non-conserved positions. In another embodiment, aminoacid residues at non-conserved positions are substituted withconservative or non-conservative residues. The techniques for obtainingthese variants, including genetic (suppressions, deletions, mutations,etc.), chemical, and enzymatic techniques, are known to persons havingordinary skill in the art.

If such allelic variations, analogues, fragments, derivatives; mutants,and modifications, including alternative mRNA splicing forms andalternative post-translational modification forms result in derivativesof the LIPG polypeptide which retain any of the biological properties ofthe LIPG polypeptide, they are included within the scope of thisinvention.

A “nucleic acid” is a polymeric compound comprised of covalently linkedsubunits called nucleotides. Nucleic acid includes polyribonucleic acid(RNA) and polydeoxyribonucleic acid (DNA), both of which may besingle-stranded or double-stranded. DNA includes cDNA, genomic DNA,synthetic DNA, and semi-synthetic DNA. The sequence of nucleotides thatencodes a protein is called the sense sequence.

An “antisense nucleic acid” is a sequence of nucleotides that iscomplementary to the sense sequence. Antisense nucleic acids can be usedto down regulate or block the expression of the polypeptide encoded bythe sense strand.

“Isolated nucleic acid” means a nucleic acid which is substantially freeof those compounds that are normally associated therewith in its naturalstate. “Isolated” is not meant to exclude artificial or syntheticmixtures with other compounds, or the presence of impurities which donot interfere with biological activity, and which may be present, forexample, due to incomplete purification, addition of stabilizers, orcompounding into a pharmaceutically acceptable preparation.

The phrase “a nucleic acid which hybridizes at high stringency” meansthat the hybridized nucleic acids are able to withstand a washing underhigh stringency conditions. An example of high stringency washingconditions for DNA-DNA hybrids is 0.1×SSC, 0.5% SDS at 68° C. Otherconditions of high stringency washing are known to persons havingordinary skill in the art.

“Regulatory region” means a nucleic acid sequence which regulates theexpression of a nucleic acid. A regulatory region may include sequenceswhich are naturally responsible for expressing a particular nucleic acid(a homologous region) or may include sequences of a different origin(responsible for expressing different proteins or even syntheticproteins). In particular, the sequences can be sequences of eukaryoticor viral genes or derived sequences which stimulate or represstranscription of a gene in a specific or non-specific manner and in aninducible or non-inducible manner. Regulatory regions include origins ofreplication, RNA splice sites, enhancers, transcriptional terminationsequences, signal sequences which direct the polypeptide into thesecretory pathways of the target cell, and promoters.

A regulatory region from a “heterologous source” is a regulatory regionwhich is not naturally associated with the expressed nucleic acid.Included among the heterologous regulatory regions are regulatoryregions from a different species, regulatory regions from a differentgene, hybrid regulatory sequences, and regulatory sequences which do notoccur in nature, but which are designed by one having ordinary skill inthe art.

A “vector” is any means for the transfer of a nucleic acid according tothe invention into a host cell. The term “vector” includes both viraland nonviral means for introducing the nucleic acid into a prokaryoticor eukaryotic cell in vitro, ex vivo or in vivo. Non-viral vectorsinclude plasmids, liposomes, electrically charged lipids (cytofectins),DNA-protein complexes, and biopolymers. Viral vectors includeretrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpessimplex, Epstein-Barr and adenovirus vectors. In addition to nucleicacid according to the invention, a vector may also contain one or moreregulatory regions, and/or selectable markers useful in selecting,measuring, and monitoring nucleic acid transfer results (transfer towhich tissues, duration of expression, etc.).

A “recombinant cell” is a cell which contains a nucleic acid which isnot naturally present in the cell. “Recombinant cell” includes highereukaryotic cells such as mammalian cells, lower eukaryotic cells such asyeast cells, prokaryotic cells, and archaebacterial cells.

“Pharmaceutically acceptable carrier” includes diluents and fillerswhich are pharmaceutically acceptable for methods of administration, aresterile, and may be aqueous or oleaginous suspensions formulated usingsuitable dispersing or wetting agents and suspending agents. Theparticular pharmaceutically acceptable carrier and the ratio of activecompound to carrier are determined by the solubility and chemicalproperties of the composition, the particular mode of administration,and standard pharmaceutical practice.

A “lipase” is a protein which can enzymatically cleave a lipidsubstrate.

A “phospholipase” is a protein which can enzymatically cleave aphospholipid substrate.

A “triacylglycerol lipase” is a protein which can enzymatically cleave atriacylglyceride substrate.

“Phosphatidylcholine” is a glycerol phospholipid. Phosphatidylcholine isalso known as lecithin.

“Lipid profile” means the set of concentrations of cholesterol,triglyceride, lipoprotein cholesterol and other lipids in the body of ahuman or other animal.

An “undesirable lipid profile” is the condition in which theconcentrations of cholesterol, triglyceride, or lipoprotein cholesterolare outside of the age- and gender-adjusted reference ranges. Generally,a concentration of total cholesterol >200 mg/dl, of plasmatriglycerides >200 mg/dl, of LDL cholesterol >130 mg/dl, of HDLcholesterol <39 mg/dl, or a ratio of total cholesterol to HDLcholesterol >4.0 is considered to be an undesirable lipid profile. Anundesirable lipid profile is associated with a variety of pathologicalconditions, including hyperlipidaemias, diabetes hypercholesterolaemia,atherosclerosis, and other forms of coronary artery disease.

A “ribozyme” is an RNA molecule which can function as an enzyme.

A “neutralizing antibody” is an antibody which can bind to an LIPGpolypeptide and lower or eliminate the enzymatic activity of the LIPGpolypeptide. These antibodies may be monoclonal antibodies or polyclonalantibodies. The present invention includes chimeric, single chain, andhumanized antibodies, as well as Fab fragments and the products of anFab expression library, and Fv fragments and the products of an Fvexpression library.

An “inhibitory molecule” or “inhibitor” is a molecule which lowers oreliminates the expression of the LIPG polypeptide or which lowers oreliminates the enzymatic activity of the LIPG polypeptide.

An “enhancer molecule” or “enhancer” is a molecule which increases theexpression of the LIPG polypeptide or which increases the enzymaticactivity of the LIPG polypeptide.

A “liposome” is an artificial or naturally-occurring phospholipidvesicle.

A “cationic liposome” is a liposome having a net positive electricalcharge.

The sections which follow discuss the elements used in the claimedmethods and compositions and the preferred embodiments of theseelements.

Polypeptides

The present invention utilizes polypeptides encoded by LIPG which aremembers of the triacylglycerol lipase family, and which comprise a 39 kDcatalytic domain of the triacylglycerol lipase family, e.g., having thesequence SEQ ID NO: 10. In certain embodiments of the present invention,an isolated LIPG polypeptide comprising the sequence SEQ ID NO: 6 andhaving an apparent molecular weight of about 40 kD on a 10% SDS-PAGE gelis utilized. In another embodiment of the present invention, an isolatedLIPG polypeptide comprising the sequence SEQ ID NO: 8 and having anapparent molecular weight of about 55 kD or 68 kD on a 10% SDS-PAGE gelis utilized. In yet another embodiment, the polypeptides utilized in thepresent invention are subfragments of these polypeptides. In still yetanother embodiment, the polypeptides used in the present invention areantibodies capable of binding to an LIPG polypeptide.

The polypeptides and proteins utilized in the present invention may berecombinant polypeptides, natural polypeptides, or syntheticpolypeptides, and may be of human, rabbit, or other animal origin. Thepolypeptides are characterized by a reproducible single molecular weightand/or multiple set of molecular weights, chromatographic response andelution profiles, amino acid composition and sequence, and biologicalactivity.

The polypeptides utilized in the present invention may be isolated fromnatural sources, such as placental extracts, human plasma, orconditioned media from cultured cells such as macrophages or endothelialcells, by using the purification procedures known to one of skill in theart.

Alternatively, the polypeptides utilized in the present invention may beprepared utilizing recombinant DNA technology, which comprises combininga nucleic acid encoding the polypeptide thereof in a suitable vector,inserting the resulting vector into a suitable host cell, recovering thepolypeptide produced by the resulting host cell, and purifying thepolypeptide recovered.

Nucleic Acids

The present invention utilizes isolated nucleic acids which encode LIPGpolypeptides.

The present invention also utilizes antisense nucleic acids which can beused to down regulate or block the expression of LIPG polypeptides invitro, ex vivo or in vivo.

The techniques of recombinant DNA technology are known to those ofordinary skill in the art. General methods for the cloning andexpression of recombinant molecules are described in Maniatis (MolecularCloning, Cold Spring Harbor Laboratories, 1982), and in Ausubel (CurrentProtocols in Molecular Biology, Wiley and Sons, 1987), which areincorporated by reference.

The nucleic acids of the present invention may be linked to one or moreregulatory regions. Selection of the appropriate regulatory region orregions is a routine matter, within the level of ordinary skill in theart. Regulatory regions include promoters, and may include enhancers,suppressors, etc.

Promoters that may be used in the present invention include bothconstitutive promoters and regulated (inducible) promoters. Thepromoters may be prokaryotic or eukaryotic depending on the host. Amongthe prokaryotic (including bacteriophage) promoters useful for practiceof this invention are lacI, lacZ, T3, T7, lambda P_(r), P_(l), and trppromoters. Among the eukaryotic (including viral) promoters useful forpractice of this invention are ubiquitous promoters (e.g. HPRT,vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin,neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDRtype, CFTR, factor VIII), tissue-specific promoters (e.g. actin promoterin smooth muscle cells, or Flt and Flk promoters active in endothelialcells), including animal transcriptional control regions, which exhibittissue specificity and have been utilized in transgenic animals:elastase I gene control region which is active in pancreatic acinarcells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, ColdSpring Harbor Symp. Quant. Biol., 50:399-409; MacDonald, 1987,Hepatology 7:425-515); insulin gene control region which is active inpancreatic beta cells (Hanahan, 1985, Nature 315:115-122),immunoglobulin gene control region which is active in lymphoid cells(Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature318:533-538; Alexander et al., 1987, Mol. Cell. Biol., 7:1436-1444),mouse mammary tumor virus control region which is active in testicular,breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495),albumin gene control region which is active in liver (Pinkert et al.,1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control regionwhich is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol.,5:1639-1648; Hammer et al., 1987, Science 235:53-58), alpha1-antitrypsin gene control region which is active in the liver (Kelseyet al., 1987, Genes and Devel., 1:161-171), beta-globin gene controlregion which is active in myeloid cells (Mogram et al., 1985, Nature315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic proteingene control region which is active in oligodendrocyte cells in thebrain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2gene control region which is active in skeletal muscle (Sani, 1985,Nature 314:283-286), and gonadotropic releasing hormone gene controlregion which is active in the hypothalamus (Mason et al., 1986, Science234:1372-1378).

Other promoters which may be used in the practice of the inventioninclude promoters which are preferentially activated in dividing cells,promoters which respond to a stimulus (e.g. steroid hormone receptor,retinoic acid receptor), tetracycline-regulated transcriptionalmodulators, cytomegalovirus immediate-early, retroviral LTR,metallothionein, SV-40, E1a, and MLP promoters. Tetracycline-regulatedtranscriptional modulators and CMV promoters are described in WO96/01313, U.S. Pat. Nos. 5,168,062 and 5,385,839, the contents of whichare incorporated herein by reference,

Viral Vector Systems

Preferably, the viral vectors used in the gene therapy methods of thepresent invention are replication defective, that is, they are unable toreplicate autonomously in the target cell. In general, the genome of thereplication defective viral vectors which are used within the scope ofthe present invention lack at least one region which is necessary forthe replication of the virus in the infected cell. These regions caneither be eliminated (in whole or in part), or be renderednon-functional by any technique known to a person skilled in the art.These techniques include the total removal, substitution (by othersequences, in particular by the inserted nucleic acid), partial deletionor addition of one or more bases to an essential (for replication)region. Such techniques may be performed in vitro (on the isolated DNA)or in situ, using the techniques of genetic manipulation or by treatmentwith mutagenic agents.

Preferably, the replication defective virus retains the sequences of itsgenome which are necessary for encapsidating the viral particles.

The retroviruses are integrating viruses which infect dividing cells.The retrovirus genome includes two LTRs, an encapsidation sequence andthree coding regions (gag, pol and env). The construction of recombinantretroviral vectors has been described: see, in particular, EP 453242,EP178220, Bernstein et al. Genet. Eng. 7 (1985) 235; McCormick,BioTechnology 3 (1985) 689, etc. In recombinant retroviral vectors, thegag, pol and env genes are generally deleted, in whole or in part, andreplaced with a heterologous nucleic acid sequence of interest. Thesevectors can be constructed from different types of retrovirus, such as,MoMuLV (“murine Moloney leukaemia virus” MSV (“murine Moloney sarcomavirus”), HaSV (“Harvey sarcoma virus”); SNV (“spleen necrosis virus”);RSV (“Rous sarcoma virus”) and Friend virus. Lentivirus vector systemsmay also be used in the practice of the present invention. Thelentiviral genome is a positive-strand polyadenylated RNA of 9,000 to10,000 base pairs containing three structural genes organized 5′ to 3′(gag, pol, env), typical of all retroviruses. For an extensive review oflentiviral systems, see Fields Virology, Second Edition, Volume 2,Chapter 55, “Lentiviruses,” pp. 1571-1589, Raven Press, New York, 1990.

In general, in order to construct recombinant retroviruses containing asequence encoding LIPG, a plasmid is constructed which contains theLTRs, the encapsidation sequence and the coding sequence. This constructis used to transfect a packaging cell line, which cell line is able tosupply in trans the retroviral functions which are deficient in theplasmid. In general, the packaging cell lines are thus able to expressthe gag, pol and env genes. Such packaging cell lines have beendescribed in the prior art, in particular the cell line PA317 (U.S. Pat.No. 4,861,719); the PsiCRIP cell line (WO90/02806) and the GP+envAm-12cell line (WO89/07150). In addition, the recombinant retroviral vectorscan contain modifications within the LTRs for suppressingtranscriptional activity as well as extensive encapsidation sequenceswhich may include a part of the gag gene (Bender et al., J. Virol. 61(1987) 1639). Recombinant retroviral vectors are purified by standardtechniques known to those having ordinary skill in the art.

The adeno-associated viruses (AAV) are DNA viruses of relatively smallsize which can integrate, in a stable and site-specific manner, into thegenome of the cells which they infect. They are able to infect a widespectrum of cells without inducing any effects on cellular growth,morphology or differentiation, and they do not appear to be involved inhuman pathologies. The AAV genome has been cloned, sequenced andcharacterized. It encompasses approximately 4700 bases and contains aninverted terminal repeat (ITR) region of approximately 145 bases at eachend, which serves as an origin of replication for the virus. Theremainder of the genome is divided into two essential regions whichcarry the encapsidation functions: the left-hand part of the genome,which contains the rep gene involved in viral replication and expressionof the viral genes; and the right-hand part of the genome, whichcontains the cap gene encoding the capsid proteins of the virus.

The use of vectors derived from the AAVs for transferring genes in vitroand in vivo has been described (see WO 91/18088; WO 93/09239; U.S. Pat.No. 4,797,368, U.S. Pat. No. 5,139,941, EP 488 528). These publicationsdescribe various AAV-derived constructs in which the rep and/or capgenes are deleted and replaced by a gene of interest, and the use ofthese constructs for transferring the said gene of interest in vitro(into cultured cells) or in vivo, (directly into an organism). Thereplication defective recombinant AAVs utilized in the present inventioncan be prepared by cotransfecting a plasmid containing the nucleic acidsequence of interest flanked by two AAV inverted terminal repeat (ITR)regions, and a plasmid carrying the AAV encapsidation genes (rep and capgenes), into a cell line which is infected with a human helper virus(for example an adenovirus). The AAV recombinants which are produced arethen purified by standard techniques. The invention also relates,therefore, to an AAV-derived recombinant virus whose genome encompassesa sequence encoding an LIPG polypeptide flanked by the AAV ITRs. Theinvention also relates to a plasmid encompassing a sequence encoding anLIPG polypeptide flanked by two ITRs from an AAV. Such a plasmid can beused as it is for transferring the LIPG sequence, with the plasmid,where appropriate, being incorporated into a liposomal vector(pseudo-virus).

In a preferred embodiment, the vector utilized in the present inventionis an adenovirus vector.

Adenoviruses are eukaryotic DNA viruses that can be modified toefficiently deliver a nucleic acid to a variety of cell types.

Various serotypes of adenovirus exist. Of these serotypes, preference isgiven, within the scope of the present invention, to using type 2 ortype 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animalorigin (see WO94/26914). Those adenoviruses of animal origin which canbe used within the scope of the present invention include adenovirusesof canine, bovine, murine (example: Mav1, Beard et al., Virology 75(1990) 81), ovine, porcine, avian, and simian (example: SAV) origin.Preferably, the adenovirus of animal origin is a canine adenovirus, morepreferably a CAV2 adenovirus (e.g. Manhattan or A26/61 strain (ATCCVR-800), for example).

Preferably, the replication defective adenoviral vectors comprise theITRs, an encapsidation sequence and the nucleic acid of interest. Stillmore preferably, at least the E1 region of the adenoviral vector isnon-functional. The deletion in the E1 region preferably extends fromnucleotides 455 to 3329 in the sequence of the Ad5 adenovirus. Otherregions may also be modified, in particular the E3 region (WO95/02697),the E2 region (WO94/28938), the E4 region (WO94/28152, WO94/12649 andWO95/02697), or in any of the late genes L1-L5. Defective retroviralvectors are disclosed in WO95/02697.

In a preferred embodiment, the adenoviral vector has a deletion in theE1 and E4 regions. In another preferred embodiment, the adenoviralvector has a deletion in the E1 region into which the E4 region and thesequence encoding LLG are inserted (see FR94 13355).

The replication defective recombinant adenoviruses can be prepared byany technique known to the person skilled in the art (Levrero et al.,Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). Inparticular, they can be prepared by homologous recombination between anadenovirus and a plasmid which carries, inter alia, the DNA sequence ofinterest. The homologous recombination is effected followingcotransfection of the said adenovirus and plasmid into an appropriatecell line. The cell line which is employed should preferably (i) betransformable by the said elements, and (ii) contain the sequences whichare able to complement the part of the genome of the replicationdefective adenovirus, preferably in integrated form in order to avoidthe risks of recombination. Examples of cell lines which may be used arethe human embryonic kidney cell line 293 (Graham et al., J. Gen. Virol.36 (1977) 59) which contains the left-hand portion of the genome of anAd5 adenovirus (12%) integrated into its genome, and cell lines whichare able to complement the E1 and E4 functions, as described inapplications WO94/26914 and WO95/02697. Recombinant adenoviruses arerecovered and purified using standard molecular biological techniques,which are well known to one of ordinary skill in the art.

Antisense Nucleic Acids

The down regulation of gene expression using antisense nucleic acids canbe achieved at the translational or transcriptional level. Antisensenucleic acids of the invention are preferably nucleic acid fragmentscapable of specifically hybridizing with all or part of a nucleic acidencoding LIPG or the corresponding messenger RNA. In addition, antisensenucleic acids may be designed or identified which decrease expression ofthe LIPG gene by inhibiting splicing of its primary transcript. Withknowledge of the structure and partial sequence of the LIPG gene, suchantisense nucleic acids can be designed and tested for efficacy.

The antisense nucleic acids are preferably oligonucleotides and mayconsist entirely of deoxyribo-nucleotides, modifieddeoxyribonucleotides, or some combination of both. The antisense nucleicacids can be synthetic oligonucleotides. The oligonucleotides may bechemically modified, if desired, to improve stability and/orselectivity. Since oligonucleotides are susceptible to degradation byintracellular nucleases, the modifications can include, for example, theuse of a sulfur group to replace the free oxygen of the phosphodiesterbond. This modification is called a phosphorothioate linkage.Phosphorothioate antisense oligonucleotides are water soluble,polyanionic, and resistant to endogenous nucleases. In addition, when aphosphorothioate antisense oligonucleotide hybridizes to its targetsite, the RNA-DNA duplex activates the endogenous enzyme ribonuclease(Rnase) H, which cleaves the mRNA component of the hybrid molecule.

In addition, antisense oligonucleotides with phosphoramidite andpolyamide (peptide) linkages can be synthesized. These molecules shouldbe very resistant to nuclease degradation. Furthermore, chemical groupscan be added to the 2′ carbon of the sugar moiety and the 5 carbon (C-5)of pyrimidines to enhance stability and facilitate the binding of theantisense oligonucleotide to its target site. Modifications may include2′ deoxy, O-pentoxy, O-propoxy, O-methoxy, fluoro, methoxyethoxyphosphoro-thioates, modified bases, as well as other modifications knownto those of skill in the art.

The antisense nucleic acids can also be DNA sequences whose expressionin the cell produces RNA complementary to all or part of the LIPG mRNA.Antisense nucleic acids can be prepared by expression of all or part ofa sequence selected from the group consisting of SEQ ID No. 2, SEQ IDNo. 3, SEQ ID No. 7, or SEQ ID No. 11, in the opposite orientation, asdescribed in EP 140308. Any length of antisense sequence is suitable forpractice of the invention so long as it is capable of down-regulating orblocking expression of LIPG. Preferably, the antisense sequence is atleast 20 nucleotides in length. The preparation and use of antisensenucleic acids, DNA encoding antisense RNAs and the use of oligo andgenetic antisense is disclosed in WO92/15680, the contents of which areincorporated herein by reference.

One approach to determining the optimum fragment of LIPG to use in anantisense nucleic acid treatment method involves preparing randomfragments of LIPG cDNA by mechanical shearing, enzymatic treatment, andcloning the fragment into any of the vector systems described herein.Individual clones or pools of clones are used to infect LIPG-expressingcells, and effective antisense LIPG cDNA fragments are identified bymonitoring LIPG expression at the RNA or protein level.

The retroviral, adeno-associated viral, and adenoviral vector systemsdiscussed hereinabove may all be used to introduce and express antisensenucleic acids in cells. Antisense synthetic oligonucleotides may beintroduced in a variety of ways, including the methods discussedhereinbelow.

Ribozymes

Reductions in the levels of LIPG polypeptide may be accomplished usingribozymes. Ribozymes are catalytic RNA molecules (RNA enzymes) that haveseparate catalytic and substrate binding domains. The substrate bindingsequence combines by nucleotide complementarity and, possibly,nonhydrogen bond interactions with its target sequence. The catalyticportion cleaves the target RNA at a specific site. The substrate domainof a ribozyme can be engineered to direct it to a specified mRNAsequence. The ribozyme recognizes and then binds a target mRNA throughcomplementary base-pairing. Once it is bound to the'correct target site,the ribozyme acts enzymatically to cut the target mRNA. Cleavage of theLIPG mRNA by a ribozyme destroys its ability to direct synthesis of LIPGpolypeptide. Once the ribozyme has cleaved its target sequence, it isreleased and can repeatedly bind and cleave at other LIPG mRNAs.

In preferred embodiments of this invention, the ribozyme is formed in ahammerhead motif. Other forms include a hairpin motif, a hepatitis deltavirus, group I intron or RnaseP RNA (in association with an RNA guidesequence) motif or Neurospora VS RNA motif. Hammerhead motifs aredescribed by Rossi et al., 1992, Aids Research and Human Retroviruses,8, 183. Hairpin motifs are described in Hampel and Tritz, 1989,Biochemistry, 28, 4929, and Hampel et al., 1990, Nucleic Acids Res., 18,299. The hepatitis delta virus motif is described by Perrotta and Been,1992, Biochemistry, 31, 16, the RnaseP motif is described byGuerrier-Takada et al., 1983, Cell, 35, 849, the Neurospora VS RNAribozyme motif is described by Collins (Saville and Collins, 1990, Cell,61, 685-696; Saville and Collins, 1991, Proc. Natl. Acad. Sci. USA, 88,8826-8830; Collins and Olive, 1993, Biochemistry, 32, 2795-2799) theGroup I intron motif is described by Cech et al., U.S. Pat. No.4,987,071.

One approach in preparing a ribozyme is to chemically synthesize anoligodeoxyribonucleotide with a ribozyme catalytic domain (˜20nucleotides) flanked by sequences that hybridize to the target LIPG mRNAafter transcription. The oligodeoxyribonucleotide is amplified by usingthe substrate binding sequences as primers. The amplification product iscloned into a eukaryotic expression vector.

Ribozymes possessing a hammerhead or hairpin structure are readilyprepared since these catalytic RNA molecules can be expressed withincells from eukaryotic promoters (e.g., Scanlon et al., 1991, Proc. Natl.Acad. Sci. USA, 88, 10591-5; Kashani-Sabet et al., 1992, Antisense Res.Dev., 2, 3-15; Dropulic et al., 1992, J. Virol., 66, 1432-41;Weerasinghe et al., 1991, J. Virol., 65, 5531-4; Ojwang et al., 1992,Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992, NucleicAcids Res., 20, 4581-9; Sarver et al., 1990, Science, 247, 1222-1225)).A ribozyme of the present invention can be expressed in eukaryotic cellsfrom the appropriate DNA vector. If desired, the activity of theribozyme may be augmented by its release from the primary transcript bya second ribozyme (Ohkawa et al., 1992, Nucleic Acids Symp. Ser., 27,15-6; Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura etal., 1993, Nucleic Acids Res., 21, 3249-55).

In one approach to preparing ribozymes, ribozymes are expressed fromtranscription units inserted into DNA, RNA, or viral vectors.Transcription of the ribozyme sequences are driven from a promoter foreukaryotic RNA polymerase I (pol (I), RNA polymerase II (pol II), or RNApolymerase III (pol III). Transcripts from pol II or pol III promoterswill be expressed at high levels in all cells; the levels of a given polII promoter in a given cell type will depend on nearby gene regulatorysequences. Prokaryotic RNA polymerase promoters are also used, providingthat the prokaryotic RNA polymerase enzyme is expressed in theappropriate cells (Elroy-Stein and'Moss, 1990, Proc. Natl. Acad. Sci.USA, 87, 6743-7; Gao and Huang 1993, Nucleic Acids Res., 21, 2867-72;Lieber et al., 1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990,Mol. Cell. Biol., 10, 4529-37). It has been demonstrated that ribozymesexpressed from these promoters can function in mammalian cells(Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3-15; Ojwang etal., 1992, Proc. Natil. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992Nucleic Acids Res., 20, 4581-9; Yu et al., 1993, Proc. Natl. Acad. Sci.USA, 90, 6340-4; L'Huillier et al., 1992, EMBO J., 11, 4411-8;Lisziewicz et al., 1993, Proc. Natl. Acad. Sci. USA, 90, 8000-4).

In one embodiment of the present invention, a transcription unitexpressing a ribozyme that cleaves LIPG RNA is inserted into a plasmidDNA vector, a retrovirus vector, an adenovirus DNA viral vector or anadeno-associated virus vector. The recombinant vectors are preferablyDNA plasmids or adenovirus vectors. However, other mammalian cellvectors that direct the expression of RNA may be used for this purpose.The vectors are delivered as recombinant viral particles. DNA may bedelivered alone or complexed with various vehicles. The DNA, DNA/vehiclecomplexes, or the recombinant virus particles are locally administeredto the site of treatment, as discussed below. Preferably, recombinantvectors capable of expressing the ribozymes are locally delivered asdescribed below, and persist in target cells. Once expressed, theribozymes cleave the target LIPG mRNA.

Ribozymes may be administered to a patient by a variety of methods. Theymay be added directly to target tissues, complexed with cationic lipids,packaged within liposomes, or delivered to target cells by other methodsknown in the art. Localized administration to the desired tissues may bedone by catheter, infusion pump or stent, with or without incorporationof the ribozyme in biopolymers as discussed hereinbelow. Alternativeroutes of delivery include, but are not limited to, intravenousinjection, intramuscular injection, subcutaneous injection, aerosolinhalation, oral (tablet or pill form), topical, systemic, ocular,intraperitoneal and/or intrathecal delivery. More detailed descriptionsof ribozyme delivery and administration are provided in Sullivan et al.,PCT WO94/02595 and Draper et al., PCT WO93/23569, which are incorporatedby reference herein.

Non-Viral Delivery Systems

Certain non-viral systems have been used in the art and can facilitateintroduction of DNA encoding the LIPG polypeptides or antisense nucleicacids into a patient.

A DNA vector encoding a desired LIPG polypeptide or antisense sequencecan be introduced in vivo by lipofection. For the past decade, there hasbeen increasing use of liposomes for encapsulation and transfection ofnucleic acids in vitro. Synthetic cationic lipids designed to limit thedifficulties and dangers encountered with liposome mediated transfectioncan be used to prepare liposomes for in vivo transfection of a geneencoding a marker [Felgner, et. al., Proc. Natl. Acad. Sci. U.S.A.84:7413-7417 (1987); see Mackey, et al., Proc. Natl. Acad. Sci. U.S.A.85:8027-8031 (1988); Ulmer et al., Science 259:1745-1748 (1993)]. Theuse of cationic lipids may promote encapsulation of negatively chargednucleic acids, and also promote fusion with negatively charged cellmembranes [Feigner and Ringold, Science 337:387-388 (1989)].Particularly useful lipid compounds and compositions for transfer ofnucleic acids are described in International Patent PublicationsWO95/18863 and WO96/17823, and in U.S. Pat. No. 5,459,127. The use oflipofection to introduce exogenous genes into the specific organs invivo has certain practical advantages. Molecular targeting of liposomesto specific cells represents one area of benefit. It is clear thatdirecting transfection to particular cell types would be particularlyadvantageous in a tissue with cellular heterogeneity, for example,pancreas, liver, kidney, and the brain. Lipids may be chemically coupledto other molecules for the purpose of targeting [see Mackey, et. al.,supra]. Targeted peptides, e.g., hormones or neurotransmitters, andproteins for example, antibodies, or non-peptide molecules could becoupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of anucleic acid in vivo, for example, a cationic oligopeptide (e.g.,International Patent Publication, WO95/21931), peptides derived from DNAbinding proteins (e.g., International Patent Publication WO96/25508), ora cationic polymer (e.g., International Patent Publication WO95/21931).

It is also possible to introduce A DNA vector encoding a LIPGpolypeptide or antisense sequence in vivo as a naked DNA plasmid (seeU.S. Pat. Nos. 5,693,622, 5,589,466 and 5,580,859). Naked DNA vectorsfor gene therapy can be introduced into the desired host cells bymethods known in the art, e.g., transfection, electroporation,microinjection, transduction, cell fusion, DEAE dextran, calciumphosphate precipitation, use of a gene gun, or use of a DNA vectortransporter [see, e.g., Wu et al., J. Biol. Chem. 267:963-967 (1992); Wuand Wu, J. Biol. Chem. 263:14621-14624 (1988); Hartmut et al., CanadianPatent Application No. 2,012,311, filed Mar. 15, 1990; Williams et al.,Proc. Natl. Acad. Sci. USA 88:2726-2730 (1991)]. Receptor-mediated DNAdelivery approaches can also be used [Curiel et al., Hum. Gene Ther.3:147-154 (1992); Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)].

Antibodies

The present invention provides antibodies against the LIPG polypeptide.These antibodies may be monoclonal antibodies or polyclonal antibodies.The present invention includes chimeric, single chain, and humanizedantibodies, as well as Fab fragments and the products of an Fabexpression library, and Fv fragments and the products of an Fvexpression library.

Polyclonal antibodies may be prepared against an antigenic fragment ofan LIPG polypeptide, as described in the Examples section hereinbelow.Antibodies may also be generated against the intact LIPG protein orpolypeptide, or against a fragment, derivative, or epitope of theprotein or polypeptide. Antibodies may be obtained following theadministration of the protein, polypeptide, fragment, derivative, orepitope to an animal, using the techniques and procedures known in theart.

Monoclonal antibodies may be prepared using the method of Mishell, B.B., et al., Selected Methods In Cellular Immunology, (W.H. Freeman, ed.)San Francisco (1980). Briefly, a polypeptide of the present invention isused to immunize spleen cells of Balb/C mice. The immunized spleen cellsare fused with myeloma cells. Fused cells containing spleen and myelomacell characteristics are isolated by growth in HAT medium, a mediumwhich kills both parental cells, but allows the fused products tosurvive and grow.

The monoclonal antibodies of the present invention may be “humanized” toprevent the host from mounting an immune response to the antibodies. A“humanized antibody” is one in which the complementarity determiningregions (CDRs) and/or other portions of the light and/or heavy variabledomain framework are derived from a non-human immunoglobulin, but theremaining portions of the molecule are derived from one or more humanimmunoglobulins. Humanized antibodies also include antibodiescharacterized by a humanized heavy chain associated with a donor oracceptor unmodified light chain or a chimeric light chain, or viceversa. The humanization of antibodies may be accomplished by methodsknown in the art (see, e.g. G. E. Mark and E. A. Padlan, “Chapter 4.Humanization of Monoclonal Antibodies”, The Handbook of ExperimentalPharmacology Vol. 113, Springer-Verlag, New York, 1994). Transgenicanimals may be used to express humanized antibodies.

Techniques known in the art for the production of single chainantibodies can be adapted to produce single chain antibodies to theimmunogenic polypeptides and proteins of the present invention.

In a preferred embodiment, an anti-LIPG antibody is used to bind to andinhibit the enzymatic activity of LIPG in a patient.

The anti-LIPG antibodies are also useful in assays for detecting orquantitating levels of LIPG. In one embodiment, these assays provide aclinical diagnosis and assessment of LIPG in various disease states anda method for monitoring treatment efficacy. These anti-LIPG antibodiesmay additionally be used to quantitate LIPG in a tissue sample in orderto predict further susceptibility to lowered levels of HDL cholesteroland apolipoprotein AI.

Methods of Identifying and Utilizing Inhibitory Molecules and EnhancerMolecules

The present invention provides methods of screening small moleculelibraries or natural product sources for enhancers (agonists) orco-activators including proteinaceous co-activators or inhibitors(antagonists) of LIPG activity. A potential enhancer or inhibitor iscontacted with LIPG protein and a substrate of LIPG, and the ability ofthe potential enhancer or inhibitor to enhance or inhibit LIPG activityis measured.

These screening methods may also be used to determine if a compound canfunction as a substrate specific enhancer or inhibitor, that is, whethera compound can enhance the enzymatic activity of LIPG toward onesubstrate while lowering or maintaining a given level of enzymaticactivity for a different substrate, for example, the LIPG polypeptide ofthe present invention utilizes HDL cholesterol as a substrate and alsoutilizes LDL cholesterol and VLDL cholesterol as substrates. In certainembodiments, it is desirable to isolate and identify substrate specificenhancers or inhibitors which enhance the enzymatic activity of the LIPGpolypeptide towards LDL cholesterol or VLDL cholesterol while loweringor maintaining the normal level of enzymatic activity for HDLcholesterol.

The LIPG protein used in these methods can be produced recombinantly ina variety of host cells, including mammalian cells, baculovirus-infectedinsect cells, yeast, and bacteria. LIPG expression in stably transfectedCHO cells can be optimized by methotrexate amplification of the cells.LIPG protein can also be purified from natural sources such as humanplasma, placental extracts, or conditioned media from culturedendothelial cells, THP-1 cells, or macrophages.

The optimization of assay parameters including pH, ion concentrations,temperature, concentration of substrate, and emulsification conditionsare determined empirically by one having ordinary skill in the art.

The fatty acid substituents of the substrates may vary in chain lengthas well as in degree and position of unsaturation. The substrates may beradiolabelled in any of several positions. Phospholipid substrates suchas phosphatidylcholine can be radiolabelled, for example, in the Sn-1 orSn-2 fatty acid position, or in the glycerol, phosphate, or polar headgroup (choline in the case of phosphatidylcholine).

As an alternative to radiolabeled substrates, other classes of labeledsubstrates, such as fluorescent substrates or thio-containingsubstrates, can also be used in the screening methods.

Fluorescent substrates are particularly useful in screening assaysbecause enzymatic catalysis can be measured continuously by measuringfluorescence intensity, without the physical separation (extraction) ofthe products from the substrates. An example of a fluorescentphosphatidylcholine substrate isC₆NBD-PC{1-acyl-2-[6-(nitro-2,1,3-benzoxadiazol-4-yl)amino]caproylphosphatidylcholine.

The thio-containing substrates include1,2-bis(hexanoylthio)-1,2-dideoxy-sn-glycero-3-phosphorylcholine (L. J.Reynolds, W. N. Washburn, R. A. Deems, and E. A. Dennis, 1991. Methodsin Enzymology 197: 3-23; L. Yu and E. A. Dennis, 1991. Methods inEnzymology 197: 65-75; L. A. Wittenauer, K. Shirai, R. L. Jackson, andJ. D. Johnson, 1984. Biochem. Biophys. Res. Commun. 118: 894-901).

In addition to inhibitory and enhancer molecules which operate at thelevel of enzymatic activity, there are inhibitory and enhancer moleculeswhich operate at the level of expression of the LIPG gene. One methodfor identifying compounds which are able to enhance or inhibit theexpression of LIPG is to use a reporter gene system. These systemsutilize reporter gene expression vectors which include a cloning siteinto which a given promoter may be cloned upstream of a “reporter gene”which can be easily detected and quantified. One of skill in the artcould readily identify and subclone the promoter for the LIPG gene aswell as other control sequences into a commercially available reportergene expression vector. The expression vector is transferred into hostcells and the cells are exposed to a test compound (a putative inhibitoror enhancer molecule) to determine the effect of the test compound onexpression of the reporter gene product. In particular, the cells areassayed for the presence of the reporter gene product by directlymeasuring the amount of reporter mRNA, the reporter protein itself orthe enzymatic activity of the reporter protein. Ideally, the reportergene is not endogenously expressed in the cell type of interest andlends itself to sensitive, quantitative and rapid assays. A variety ofreporter assay constructs are commercially available and severalreporter genes and assays have been developed and can be readilyprepared by those of skill in the art. The most popular systems formonitoring genetic activity in eukaryotic cells include thechloramphenicol acetyltransferase (CAT), β-galactosidase, fireflyluciferase, growth hormone (GH), β-glucurorudase (GUS), alkalinephosphatase (AP), green fluorescent protein (GFP) and Renillaluciferase. Reporter assay constructs can be purchased from a variety ofsources including Promega and Invitrogen.

As mentioned above, reporter gene activity can be detected by assayingfor the reporter mRNA or the reporter protein. The reporter mRNA can bedetected by northern blot analysis, ribonuclease protection assays orRT-PCR. While these assays are more direct than measuring proteinexpression, many assays have been developed to measure the presence ofthe reporter protein rather than the mRNA present in a cell. Reporterproteins can be assayed by spectrophotometry or by detecting enzymaticactivity. Reporter protein levels may also be measured withantibody-based assays. In general, the enzymatic assays are verysensitive and are a preferred method of monitoring reporter geneexpression.

Compositions

The present invention provides compositions in a biologically compatible(biocompatible) solution, comprising the polypeptides, nucleic acids,vectors, and antibodies of the invention. A biologically compatiblesolution is a solution in which the polypeptide, nucleic acid, vector,or antibody of the invention is maintained in an active form, e.g., in aform able to effect a biological activity. For example, a polypeptide ofthe invention would have phospholipase activity; a nucleic acid would beable to replicate, translate a message, or hybridize to a complementarynucleic acid; a vector would be able to transfect a target cell; anantibody would bind a polypeptide of the invention. Generally, such abiologically compatible solution will be an aqueous buffer, e.g., Tris,phosphate, or HEPES buffer, containing salt ions. Usually theconcentration of salt ions will be similar to physiological levels. In aspecific embodiment, the biocompatible solution is a pharmaceuticallyacceptable composition. Biologically compatible solutions may includestabilizing agents and preservatives.

Such compositions can be formulated for administration by topical, oral,parenteral, intranasal, subcutaneous, and intraocular, routes.Parenteral administration is meant to include intravenous injection,intramuscular injection, intraarterial injection or infusion techniques.The composition may be administered parenterally in dosage unitformulations containing standard, well known nontoxic physiologicallyacceptable carriers, adjuvants and vehicles as desired.

The preferred sterile injectable preparations can be a solution orsuspension in a nontoxic parenterally acceptable solvent or diluent.Examples of pharmaceutically acceptable carriers are saline, bufferedsaline, isotonic saline (e.g. monosodium or disodium phosphate, sodium,potassium, calcium or magnesium chloride, or mixtures of such salts),Ringer's solution, dextrose, water, sterile water, glycerol, ethanol,and combinations thereof. 1,3-butanediol and sterile fixed oils areconveniently employed as solvents or suspending media. Any bland fixedoil can be employed including synthetic mono- or di-glycerides. Fattyacids such as oleic acid also find use in the preparation ofinjectables.

The composition medium can also be a hydrogel which is prepared from anybiocompatible or non-cytotoxic (homo or hetero) polymer, such as ahydrophilic polyacrylic acid polymer that can act as a drug absorbingsponge. Such polymers have been described, for example, in applicationWO93/08845, the entire contents of which are hereby incorporated byreference. Certain of them, such as, in particular, those obtained fromethylene and/or propylene oxide are commercially available. A hydrogelcan be deposited directly onto the surface of the tissue to be treated,for example during surgical intervention.

Another preferred embodiment of the present invention relates to apharmaceutical composition comprising a replication defectiverecombinant virus and poloxamer. More specifically, the inventionrelates to a composition comprising a replication defective recombinantvirus comprising a nucleic acid encoding an LIPG polypeptide andpoloxamer. A preferred poloxamer is Poloxamer 407, which is commerciallyavailable (BASF, Parsippany, N.J.) and is a non-toxic, biocompatiblepolyol, and is most preferred. A poloxamer impregnated with recombinantviruses may be deposited directly on the surface of the tissue to betreated, for example during a surgical intervention. Poloxamer possessesessentially the same advantages as hydrogel while having a lowerviscosity.

Methods of Treatment

The present invention provides methods of treatment which comprise theadministration to a human or other animal of an effective amount of acomposition of the invention.

Effective amounts may vary, depending on the age, type and severity ofthe condition to be treated, body weight, desired duration of treatment,method of administration, and other parameters. Effective amounts aredetermined by a physician or other qualified medical professional. Inmost cases, the dosage levels may be adjusted so that the desired levelsof HDL cholesterol and apolipoprotein AI are achieved and maintained.Similarly, the dosage levels may be adjusted to lower the VLDLcholesterol and LDL cholesterol levels to acceptable levels and bringthe ratio HDL cholesterol to LDL cholesterol and VLDL cholesterol towithin desirable levels.

Polypeptides according to the invention are generally administered indoses of about 0.01 mg/kg to about 100 mg/kg, preferably about 0.1 mg/kgto about 50 mg/kg, and most preferably about 1 mg/kg to about 10 mg/kgof body weight per day.

Neutralizing antibodies according to the invention may be delivered as abolus only, infused over time or both administered as a bolus andinfused over time. Although the dosage amount will vary based on theparameters above, and on the binding ability of the antibody, a dose 0.2to 0.6 mg/kg may be given as a bolus followed by a 2 to 12 hour infusionperiod. Alternatively, multiple bolus injections are administered everyother day or every third or fourth day as needed. Dosage levels may beadjusted as determined by HDL cholesterol levels and/or VLDL and LDLcholesterol levels.

As discussed hereinabove, recombinant viruses may be used to introduceboth DNA encoding LIPG and subfragments of LIPG as well as antisensenucleic acids. Recombinant viruses according to the invention aregenerally formulated and administered in the form of doses of betweenabout 10⁴ and about 10¹⁴ pfu. In the case of AAVs and adenoviruses,doses of from about 10⁶ to about 10¹¹ pfu are preferably used. The termpfu (“plaque-forming unit”) corresponds to the infective power of asuspension of virions and is determined by infecting an appropriate cellculture and measuring the number of plaques formed. The techniques fordetermining the pfu titre of a viral solution are well documented in theprior art.

Ribozymes according to the present invention may be administered inamounts ranging from about 5 to about 50 mg/kg/day in a pharmaceuticallyacceptable carrier. Dosage levels may be adjusted based on the measuredtherapeutic efficacy.

Appropriate levels of inhibitor or enhancer molecules may be determinedby qualified medical personnel using the parameters discussed above.

The present invention provides compositions and methods for increasingthe level of HDL cholesterol and apolipoprotein AI and lowering thelevels of VLDL and LDL cholesterol in a patient. The present inventionfurther provides methods of treating a human or other animal having anundesirable lipid profile, wherein said undesirable lipid profile is theresult of abnormally high expression of LIPG polypeptide activity.

Methods and Compositions for Lowering Levels of LIPG PolypeptideActivity

The methods for decreasing the expression of LIPG polypeptide in orderto increase the levels of HDL cholesterol and apolipoprotein AI andcorrect those conditions in which LIPG polypeptide activity contributesto a disease or disorder associated with an undesirable lipid profileinclude but are not limited to administration of a compositioncomprising an antisense nucleic acid, administration of a compositioncomprising an intracellular binding protein such as an antibody,administration of an inhibitory molecule which inhibits the enzymaticactivity of LIPG, for example, a composition comprising an expressionvector encoding a subfragment of LIPG, for example, LLGN polypeptide ora small molecular weight molecule, including administration of a smallmolecular weight compound which down regulates LIPG expression at thelevel of transcription, translation or post-translation, andadministration of a ribozyme which cleaves mRNA encoding LIPG.

Methods Utilizing Antisense Nucleic Acids

In one embodiment, a composition comprising an antisense nucleic acid isused to down-regulate or block the expression of LIPG. In one preferredembodiment, the nucleic acid encodes antisense RNA molecules. In thisembodiment, the nucleic acid is operably linked to signals enablingexpression of the nucleic acid sequence and is introduced into a cellutilizing, preferably, recombinant vector constructs, which will expressthe antisense nucleic acid once the vector is introduced into the cell.Examples of suitable vectors includes plasmids, adenoviruses,adeno-associated viruses, retroviruses, and herpes viruses. Preferably,the vector is an adenovirus. Most preferably, the vector is areplication defective adenovirus comprising a deletion in the E1 and/orE3 regions of the virus.

In another embodiment, the antisense nucleic acid is synthesized and maybe chemically modified to resist degradation by intracellular nucleases,as discussed above. Synthetic antisense oligonucleotides can beintroduced to a cell using liposomes. Cellular uptake occurs when anantisense oligonucleotide is encapsulated within a liposome. With aneffective delivery system, low, non-toxic concentrations of theantisense molecule can be used to inhibit translation of the targetmRNA. Moreover, liposomes that are conjugated with cell-specific bindingsites direct an antisense oligonucleotide to a particular tissue.

Methods Utilizing Neutralizing Antibodies and Other Binding Proteins

In another embodiment, the expression of LIPG is down-regulated orblocked by the expression of a nucleic acid sequence encoding anintracellular binding protein which is capable of selectivelyinteracting with LIPG. WO 94/29446 and WO 94/02610, the contents ofwhich are incorporated herein by reference, disclose cellulartransfection with genes encoding an intracellular binding protein. Anintracellular binding protein includes any protein capable ofselectively interacting, or binding, with LIPG in the cell in which itis expressed and of neutralizing the function of bound LLG. Preferably,the intracellular binding protein is a neutralizing antibody or afragment of a neutralizing antibody. More preferably, the intracellularbinding protein is a single chain antibody.

WO 94/02610 discloses preparation of antibodies and identification ofthe nucleic acid encoding a particular antibody. Using LIPG or afragment thereof, a specific monoclonal antibody is prepared bytechniques known to those skilled in the art. A vector comprising thenucleic acid encoding an intracellular binding protein, or a portionthereof, and capable of expression in a host cell is subsequentlyprepared for use in the method of this invention.

Alternatively, LIPG activity can be blocked by administration of aneutralizing antibody into the circulation. Such a neutralizing antibodycan be administered directly as a protein, or it can be expressed from avector (with a secretory signal).

Methods Utilizing an Inhibitory Molecule which Inhibits the EnzymaticActivity of LIPG

In another embodiment, LIPG activity is inhibited by the administrationof a composition comprising a subfragment of LIPG polypeptide, forexample, LLGN. This composition may be administered in a convenientmanner, such as by the oral, topical, intravenous, intraperitoneal,intramuscular, subcutaneous, intranasal, or intradermal routes. Thecomposition may be administered directly or it may be encapsulated (e.g.in a lipid system, in amino acid microspheres, or in globulardendrimers). The polypeptide may, in some cases, be attached to anotherpolymer such as serum albumin or polyvinyl pyrrolidone.

In another embodiment, LIPG activity is inhibited through the use ofgene therapy, that is, through the administration of a compositioncomprising a nucleic acid which encodes and directs the expression of asubfragment of LIPG, for example, LLGN.

In another embodiment, LIPG activity is inhibited through the use ofinhibitory molecules. These low molecular weight compounds interferewith LIPG's enzymatic properties or prevent its appropriate recognitionby cellular binding sites.

In a specific embodiment, the LIPG polypeptide of the present inventionalso has an affinity for heparin. LIPG polypeptide binding toextracellular heparin in the lumen of blood vessels would permit LIPG tobind to and accelerate LDL uptake by acting as a bridge between LDL andthe extracellular heparin. In the localized area of an atheroscleroticlesion, an increased level of lipase activity is hypothesized toaccelerate the atherogenic process (Zilversmit, D. B. (1995) Clin. Chem.41, 153-158; Zambon, A., Torres, A., Bijvoet, S., Gagne, C., Moojani,S., Lupien, P. J., Hayden M. R., and Brunzell, J. D. (1993) Lancet 341,1119-1121). This may be due to an increase in the binding and uptake oflipoproteins by vascular tissue mediated by lipases (Eisenberg, S.,Sehayek, E., Olivecrona, T. Vlodaysky, I. (1992) J. Clin. Invest. 90,2013-2021; Tabas, I., Li, I., Brocia R. W., Xu, S. W., Swenson T. L.Williams, K. J. (1993) J. Biol. Chem. 268, 20419-20432; Nordestgaard, B.G., and Nielsen, A. G. (1994) Curr. Opin. Lipid. 5, 252-257; Williams,K. J., and Tabas, I. (1995) Art. Thromb. and Vasc. Biol. 15, 551-561).Additionally, a high local level of lipase activity may result incytotoxic levels of fatty acids and lysophosphatidylcholine beingproduced in precursors of atherosclerotic lesions. This particularactivity of LLG may contribute to the development or progression ofatherosclerosis, particularly in the context of excessive lipid levelsin a subject due to dietary or genetic factors. Thus, the presentinvention permits inhibition of lipoprotein accumulation by inhibitingLIPG polypeptide expression or binding to lipoprotein (e.g., LDL).

Methods Utilizing an Inhibitory Molecule which Prevents LIPG GeneExpression

In another embodiment, inhibitory molecules, including small molecularweight compounds, are able to down regulate LIPG expression at the levelof transcription, translation or post-translation. In order to identifysuch inhibitory molecules, the reporter gene systems described above maybe used. These inhibitory molecules may be combined with apharmaceutically acceptable carrier and administered using conventionalmethods known in the art.

Methods Utilizing Ribozymes

Ribozymes may be administered to cells by encapsulation in liposomes, byiontophoresis, by incorporation into hydrogels, cyclodextrins,biodegradable nanocapsules, and bioadhesive microspheres or by any of avariety of other methods discussed above. The ribozyme may be deliveredto a target tissue by direct injection or by use of a catheter, infusionpump or stent. Alternative routes of delivery include intravenousinjection, intramuscular injection, subcutaneous injection, aerosolinhalation, oral (tablet or pill form), topical, systemic, ocular,intraperitoneal and/or intrathecal delivery.

In preferred embodiments, a ribozyme-encoding sequence is cloned into aDNA expression vector. Transcription of the ribozyme sequence is drivenfrom an eukaryotic RNA polymerase II (pol II), or RNA polymerase III(pol III) promoter. The expression vector can be incorporated into avariety of vectors including the viral DNA vectors such as adenovirus oradeno-associated virus vectors discussed above.

In a preferred embodiment of the invention, a transcription unitexpressing a ribozyme that cleaves LIPG RNA is inserted into anadenovirus DNA viral vector. The vector is delivered as recombinantviral particles and is locally administered to the site of treatment,through the use of a catheter, stent or infusion pump.

Administration of Apolipoprotein AI

In another embodiment, any of the methods discussed above for loweringthe levels of LIPG polypeptide activity are utilized in combination withadministration of apolipoprotein AI or an expression system capable ofexpressing apolipoprotein AI in a patient (see, for example, U.S. Pat.No. 5,866,551, which is incorporated herein by reference).

Methods and Compositions for Increasing Levels of LIPG PolypeptideActivity

The methods for increasing the expression or activity of LIPGpolypeptide to lower the levels of VLDL and LDL cholesterol include, butare not limited to, administration of a composition comprising the LIPGpolypeptide, administration of a composition comprising an expressionvector which encodes the LIPG polypeptide, administration of acomposition comprising an enhancer molecule which enhances the enzymaticactivity of the LIPG polypeptide and administration of an enhancermolecule which increases expression of the LIPG gene.

Methods Utilizing LIPG Polypeptides

In one embodiment, the level of LIPG activity is increased through theadministration of a composition comprising the LIPG polypeptide. Thiscomposition may be administered in a convenient manner, such as by theoral, topical, intravenous, intraperitoneal, intramuscular,subcutaneous, intranasal, or intradermal routes. The composition may beadministered directly or it may be encapsulated (e.g. in a lipid system,in amino acid microspheres, or in globular dendrimers). The polypeptidemay, in some cases, be attached to another polymer such as serum albuminor polyvinyl pyrrolidone.

Methods Utilizing Vectors that Express LIPG

In another embodiment, the level of LIPG is increased through the use ofgene therapy, that is, through the administration of compositioncomprising a nucleic acid which encodes and directs the expression ofthe LIPG polypeptide. In this embodiment, the LIPG polypeptide is clonedinto an appropriate expression vector. Possible vector systems andpromoters are extensively discussed above. The expression vector istransferred into the target tissue using one of the vector deliverysystems discussed above. This transfer is carried out either ex vivo ina procedure in which the nucleic acid is transferred to cells in thelaboratory and the modified cells are then administered to the human orother animal, or in vivo in a procedure in which the nucleic acid istransferred directly to cells within the human or other animal. Inpreferred embodiments, an adenoviral vector system is used to deliverthe expression vector. If desired, a tissue specific promoter isutilized in the expression vector as described above.

Non-viral vectors may be transferred into cells using any of the methodsknown in the art, including calcium phosphate coprecipitation,lipofection (synthetic anionic and cationic liposomes),receptor-mediated gene delivery, naked DNA injection, electroporationand bioballistic or particle acceleration.

Methods Utilizing an Enhancer Molecule which Enhances the EnzymaticActivity of LIPG

In another embodiment, the activity of LIPG is enhanced by enhancermolecules that increase the enzymatic activity of LIPG or increase itsappropriate recognition by cellular binding sites. These enhancermolecules may be introduced by the same methods discussed above for theadministration of polypeptides.

Methods Utilizing an Enhancer Molecule which Increases LIPG GeneExpression

In another embodiment, the level of LIPG is increased through the use ofsmall molecular weight compounds, which can upregulate LIPG expressionat the level of transcription, translation, or post-translation. Thesecompounds may be administered by the same methods discussed above forthe administration of polypeptides.

Treatment Methods Relating to Impaired Biliary Excretion

Intrahepatic cholestasis can be characterized by increased serumcholesterol and phospholipid levels. A recently described, phalloidindrug-induced intrahepatic cholestasis model in rats demonstratedsignificant increases in the serum levels of cholesterol andphospholipid (Ishizaki, K., Kinbara, S., Miyazawa, N., Takeuchi, Y.,Hirabayashi, N., Kasai, H., and Araki, T. (1997) Toxicol. Letters 90,29-34). The products of this invention may be used to treat intrahepaticcholestasis in patients that have increased serum cholesterol and/orphospholipid. In addition, this rat model also exhibited a severedecrease in biliary cholesterol excretion rates. The LIPG polypeptideand nucleic acid products of this invention may be used to treatpatients with an impaired biliary excretion system.

Intrahepatic cholestasis is also characterized by impaired bile flowfrom the liver. Recently, the loci for progressive familial intrahepaticcholestasis (PFIC or Byler disease) and benign recurrent intrahepaticcholestasis (BRIC) were mapped to 18q21-q22 (Carlton, V. E. H., Knisely,A. S., and Freimer, N. B. (1995) Hum. Mol. Genet. 4, 1049-1053 andHouwen, R. H., Baharloo, S., Blankenship, K., Raeymaekers, P., Juyn, J.,Sandkuijl, L. A., and Freimer, N. B. (1994) Nature Genet. 8, 380-386,respectively). As LLG gene maps within this chromosomal region at 18q21,the LLG gene or products of this invention may be used to treat patientswith intrahepatic cholestasis that is caused by a mutation or defectiveexpression of the PFIC/BRIC disease gene(s).

In another embodiment, the LLG gene or polypeptide products of thisinvention may be used to treat patients with intrahepatic cholestasisthat is not due to a defect in the PFIC/BRIC disease gene(s) at18q21-q22. A recent study suggested that another locus, located outsideof the 18q21-q22 region may also produce the PFIC phenotype(Strautnieks, S. S., Kagalwalla, A. F., Tanner, M. S., Gardiner, R. M.,and Thompson, R. J. (1996) J. Med. Genet. 33, 833-836). Nevertheless,administration of LLG polypeptide, either directly or via gene therapy,may alleviate this form of the condition.

Methods and Compositions for Diagnosing a Predisposition to Low HDLLevels

Given the ability of LIPG polypeptide to lower the levels of HDLcholesterol and apolipoprotein AI, the level of LIPG polypeptide in thebody may be used to determine whether an individual is predisposed tolow levels of HDL cholesterol and apolipoprotein AI. In this method, atissue sample is taken from the patient. The tissue may be blood or oneof the tissues which has been demonstrated to express LIPG as discussedin the Examples section. Measurement of the level of LIPG may beperformed by a variety of methods known to those of skill in the art. Inpreferred embodiments, an antibody directed against LIPG polypeptide maybe used to measure the level of LIPG in a tissue sample.

EXAMPLES

The following examples illustrate the invention. These examples areillustrative only, and do not limit the scope of the invention.

Example 1 Identification of a Differentially Expressed cDNA

RNA Preparation

Human monocytic THP-1 cells (Smith, P. K., Krohn, R. I., Hermanson, G.T., Mallia, A. K., Gartner, F. H. Provenzano, M. D., Fujimoto, E. K.,Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150,76-85) were cultured in RPMI-1640 medium (GIBCO) with 25 mM HEPES, 10%fetal bovine serum, 100 units/ml penicillin G sodium and 100 units/mlstreptomycin sulfate. Cells were plated onto 15 cm tissue culture dishesat 1.5×10⁷ cells/plate, and treated with 40 ng/ml phorbol 12-myristate13-acetate (Sigma) for 48 hours to induce differentiation of the cells.Human low density lipoproteins (LDL) were purchased from Calbiochem, andwere dialyzed exhaustively versus PBS at 4° C. The LDL was then dilutedto 500 μg/ml and dialyzed versus 5 μM CuSO₄ in PBS at 37° C. for 16hours. To stop oxidation, the LDL was dialyzed exhaustively versus 150mM NaCl, 0.3 mM EDTA, then filter sterilized. Protein concentration wasdetermined by the BCA method (Schuh, J. Fairclough, G. F., andHaschemeyer, R. H. (1978) Proc. Natl. Acad. Sci. USA 75, 3173-3177)(Pierce). The degree of oxidation was determined by TBARS (Chomczynski,P. (1993) Biotechniques 15, 532-537), and was between 25-30 nmol MDAequivalents/mg protein. The differentiated THP-1 cells were exposed for24 hours to either 50 μg/ml oxidized LDL or NaCl-EDTA buffer in RPMImedium with 10% lipoprotein-deficient fetal bovine serum (Sigma). Toharvest the RNA, the plates were rinsed with 10 ml of PBS, then 14 ml ofTRIZOL (Liang, P. and Pardee, A. B. (1992) Science 257, 967-971) (GIBCO)were added to each plate. The solution was pipetted several times tomix, then like samples were pooled into centrifuge tubes and 3 mlchloroform per plate were added and mixed. The tubes were centrifugedfor 15 minutes at 12000×g. After centrifugation the upper layer wastransferred to a new tube and 7.5 ml isopropanol per plate was added andmixed. The tubes were centrifuged at 12000×g for 20 minutes. The pelletwas rinsed with ice-cold 70% ethanol and dried at room temperature. Thepellets were suspended in 500 μl TE (Tris-EDTA) and treated with 200units RNase-free DNAse 1 and 200 units RNasin placental RNase inhibitor(Promega) for 30 minutes at 37° C. The RNA was purified by sequentialextractions with phenol, phenol/chloroform/isoamyl alcohol (25:24:1),and chloroform/isoamyl alcohol (24:1) followed by ethanol precipitation.

cDNA Synthesis

cDNA synthesis and PCR amplification were accomplished using protocolsfrom the Differential Display Kit, version 1.0 (Display SystemsBiotechnology, Inc.) This system is based on the technique originallydescribed by Liang and Pardee (Mead, D. A., Pey, N. K., Herrnstadt, C.,Marcil, R. A., and Smith, L. M., (1991) Bio/Technology 9, 657-663). Theprimer pairs which yielded the cDNA fragment containing the firstinformation of the lipase like gene were downstream primer 7 andupstream primer 15. The cDNA for the amplification was synthesized asfollows, using RNA derived from PMA treated THP-1 cells exposed toeither buffer or oxidized LDL: 3 μl of 25 μM downstream primer 7 and 7.5μl of diethylpyrocarbonate (DEPC)-treated water were added to 300 ng(3.0 μl) RNA from either sample of THP-1 RNA. This was heated to 70° C.for 10 minutes then chilled on ice. To this tube were added 3 μl of5×PCR buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl)(GIBCO), 3 μl 25 mMMgCl₂, 3 μl 0.1M DTT, 1.2 μl 500 μM dNTPs, 0.7 μl RNasin, and 5.6 μlDEPC-treated water. The tubes were incubated for 2 minutes at roomtemperature, after which 1.5 μl (300 units) Superscript II RNase H—reverse transcriptase (GIBCO) were added. The tubes were incubatedsequentially at room temperature for 2 minutes, 60 minutes at 37° C.,and 5 minutes at 95° C., followed by chilling on ice. PCR amplificationwas performed using a master mix containing 117 μl 10×PCR buffer (500 mMKCl, 100 mM Tris-HCl pH 8.3, 15 mM MgCl₂, and 0.01% (w/v) gelatin), 70.2μl 25 mM MgCl₂, 5.9 μl alpha-³³P dATP (10 m Ci/ml, DuPont NEN), 4.7 μl500 μM dNTP mix, 11 μl AmpliTaq DNA polymerase (5 units/μl,Perkin-Elmer), and 493.3 μl DEPC-treated water. For each reaction, 12 μlof the master mix was added to 2 μl downstream primer #7, 1 μl of cDNA,and 5 μl of upstream primer #15. The reaction mixes were heated to 94°C. for 1 minute, then thermocycled 40 times with a denaturing step of94° C. for 15 seconds, annealing step of 40° C. for 1 minute, and anextension step of 72° C. for 30 seconds. Following the 40 cycles, thereactions were incubated at 72° C. for 5 minutes and stored at 10° C.The PCR reactions were performed in a Perkin-Elmer GeneAmp System 9600thermocycler.

Four microliters of the amplification reaction were mixed with an equalvolume of loading buffer (0.2% bromphenol blue, 0.2% Xylene cyanol, 10mM EDTA pH 8.0, and 20% glycerol). Four microliters of this mix was runon a 6% nondenaturing acrylamide sequencing format gel for 3 hours at1200 volts (constant voltage). The gel was dried at 80° C. for 1.5 hoursand exposed to Kodak XAR film. An amplification product found only inthe reaction containing cDNA from THP-1 cells exposed to oxidized LDLwas identified and excised from the gel. 100 μl of DEPC-treated waterwas added to a microcentrifuge tube containing the excised gel fragmentand was incubated for 30 minutes at room temperature followed by 15minutes at 95° C.

To reamplify the PCR product, 26.5 microliters of the eluted DNA wereused in a amplification reaction that also included 5 μl 10×PCR buffer,3 μl 25 mM MgCl₂, 5 μl 500 μM dNTPs, 5 μl 2 μM downstream primer 7, 7.5μl upstream primer 15, and 0.5 μl Amplitaq polymerase. The PCR cyclingparameters and instrument were as described above. Followingamplification, 20 μl of the reamplification was analyzed on an agarosegel and 4 μl was used to subclone the PCR products into the vector pCRIIusing the TA cloning system (Frohman, M. A., Dush, M. K., and Martin, G.R. (1988) Proc. Natl. Acad. Sci. USA 85, 8998-9002) (Invitrogen).Following an overnight ligation at 14° C., the ligation products wereused to transform E. coli. Resulting transformants were picked and 3 mlovernight cultures were used in plasmid minipreparations. Insert sizeswere determined using EcoRI digestions of the plasmids and clonescontaining inserts of the approximate size of the original PCR productwere sequenced using fluorescent dye-terminator reagents (Prism, AppliedBiosystems) and an Applied Biosystems 373 DNA sequencer. The sequence ofthe PCR product is in FIG. 2. The sequence of the amplification primersis underlined.

5′RACE Reaction

Extension of the cDNA identified through RT-PCR was accomplished usingthe 5′RACE system (Loh, E. Y., Eliot, J. F., Cwirla, S., Lanier, L. L.,and Davis, M. M. (1989) Science 243, 217-219; Simms, D., Guan, N., andSitaraman, K., (1991) Focus 13, 99) (GIBCO). One microgram of the THP-1RNA (oxidized LDL treated) used initially in the differential displayreactions was utilized in the 5′RACE procedure:

1 μl (1 μg) of RNA was combined with 3 μl (3 pmol) primer 2a and 11 μlDEPC-treated water and heated to 70° C. for 10 minutes followed by 1minute on ice. 2.5 μl 10× reaction buffer (200 mM Tris-HCl pH 8.4, 500mM KCl), 3 μl 25 mM MgCl₂, 1 μl 10 mM dNTP mix, and 2.5 μl 0.1 M DTTwere added. The mix was incubated at 42° C. for 2 minutes, then 1 μlSuperscript II reverse transcriptase was added. The reaction wasincubated for an additional 30 minutes at 42° C., 15 minutes at 70° C.,and on ice for 1 minute. One microliter of RNase H (2 units) was addedand the mixture was incubated at 55° C. for 10 minutes. The cDNA waspurified using the GlassMax columns (Sambrook, J. Fritsch, E. F., andManiatis, T. (1989) Molecular Cloning: A Laboratory Manual, secondedition, Cold Spring Harbor Laboratory Press, Plainview, N.Y.) includedin the kit. The cDNA was eluted from the column in 50 μl dH₂O,lyophilized, and resuspended in 21 μl dH₂O. Tailing of the cDNA wasaccomplished in the following reaction: 7.5 μl dH₂O, 2.5 μl reactionbuffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 1.5 μl 25 mM MgCl₂, 2.5 μl2 mM dCTP, and 10 μl of the cDNA were incubated at 94° C. for 3 minutes,then 1 minute on ice. 1 μl (10 units) of terminal deoxynucleotidyltransferase was added and the mixture was incubated for 10 minutes at37° C. The enzyme was heat inactivated by incubation at 70° C. for 10minutes and the mixture was placed on ice. PCR amplification of the cDNAwas performed in the following steps: 5 μl of the tailed cDNA wasincluded in a reaction which also contained 5 μl 10×PCR buffer (500 mMKCl, 100 mM Tris-HCl pH 8.3, 15 mM MgCl₂, and 0.01% (w/v) gelatin), 1 μl10 mM dNTP mix, 2 μl (10 pmol) anchor primer, 1 μl (20 pmol) primer 3a,and 35 μl dH₂O. The reaction was heated to 95° C. for 1 minute, then 0.9μl (4.5 units) Amplitaq polymerase was added. The reaction was cycled 40times under the following conditions: 94° C. for 5 seconds, 50° C. for20 seconds, and 72° C. for 30 seconds. One microliter of this reactionwas used in a nested reamplification to increase levels of specificproduct for subsequent isolation. The reamplification included: 1 μlprimary amplification, 5 μl 10×PCR buffer, 1 μl 10 mM dNTP mix, 2 μl (20pmol) universal amplification primer, 2 μl (20 pmol) primer 4a, and 38μl dH₂O. The reaction was heated to 95° C. for 1 minute, then 0.7 μl(3.5 units) Amplitaq polymerase was added. The reaction was cycled 40times under these conditions; 94° C. for 5 seconds, 50° C. for 20seconds, and 72° C. for 30 seconds. The amplification products wereanalyzed via 0.8% agarose gel electrophoresis. A predominant product ofapproximately 1.2 kilobase pairs was detected. Two microliters of thereaction products were cloned into the pCRII vector from the TA cloningkit (Invitrogen) and incubated at 14° C. overnight. The ligationproducts were used to transform E. coli. The insert sizes of theresulting transformants were determined following EcoRI digestion.Clones containing inserts of the approximate size of the PCR productwere sequenced using fluorescent dye-terminator reagents (Prism, AppliedBiosystems) and an Applied Biosystems 373 DNA sequencer. The sequence ofthe RACE product including the EcoRI sites from the TA vector are shownin FIG. 3. The sequences of the amplimers (universal amplificationprimer and the complement to 5′RACE primer 4a) are underlined.

Example 2 Cloning and Chromosomal Localization of the LIPG Gene

cDNA Library Screening

A human placental cDNA library (Oligo dT and random primed, Cat #5014b,Lot #52033) was obtained from Clontech (Palo Alto, Calif.). Aradiolabeled probe was created by excising the insert of a plasmidcontaining the 5′RACE reaction PCR product described above. The probewas radiolabeled using the random priming technique: the DNA fragment(50-100 ng) was incubated with 1 μg of random hexamers (Gibco) at 95° C.for 10 minutes followed by 1 minute on ice. At room temperature thefollowing were added: 3 μl 10× Klenow buffer (100 mM Tris-HCl pH 7.5, 50mM MgCL₂, 57 mM dithiothreitol; New England Biolabs), 3 μl 0.5 mM dATP,dGTP, dTTP), 100 μCi α-³²PdCTP (3000 Ci/mmol, New England Nuclear), and1 μl Klenow fragment of DNA polymerase I (5 units, Gibco). The reactionwas incubated for 2-3 hours at room temperature and the reaction wasthen stopped by increasing the volume to 100 μl with TE pH 8.0 andadding EDTA to a final concentration of 1 mM. The unincorporatednucleotides were removed by raising the reaction volume to 100 μl andpassing over a G-50 spin column (Boehringer Mannheim). The resultingprobes had a specific activity greater than 5×10⁸ cpm/μg DNA.

The library was probed using established methods (Walter, P., Gilmore,R., and Blobel, G. (1984) Cell 38, 5-8). Briefly, the filters werehybridized for 24 hours at 65° C. in 4.8×SSPE (20×SSPE=3.6 M NaCl, 0.2 MNaH₂PO₄, 0.02 M EDTA, pH 7.7), 20 mM Tris-HCl pH 7.6, 1×Denhardt'ssolution (100×=2% Ficoll 400, 2% polyvinylpyrrolidone, 2% BSA), 10%dextran sulfate, 0.1% SDS, 100 μg/ml salmon sperm DNA, and 1×10⁶ cpm/mlradiolabelled probe. Filters were then washed three times for 15 minutesat room temperature in 2×SSC (1×SSC=150 mM NaCl, 15 mM sodium citrate pH7.0), 0.1% sodium dodecyl sulfate (SDS) followed by three washes for 15minutes each at 65° C. in 0.5×SSC, 0.1% SDS. Phage which hybridized tothe probe were isolated and amplified. DNA was purified from theamplified phage using LambdaSorb reagent (Promega) according to themanufacturer's instructions. The inserts were excised from the phage DNAby digestion with EcoRI. The inserts were subcloned into the EcoRI siteof a plasmid vector (Bluescript II SK, Stratagene). The sequence of theopen reading frame contained within the 2.6 kb EcoRI fragment of thecDNA was determined by automated sequencing as described above. Thesequence is shown in FIG. 4. The amino acid sequence of the predictedprotein encoded by the open reading frame is shown in FIG. 5 and hasbeen termed LLGXL. The first methionine is predicted to be encoded bynucleotide pairs 252-254. The predicted protein is 500 amino acids inlength. The first 18 amino acids form a sequence characteristic of asecretory signal peptide (Higgins, D. G., and Sharp, P. M. (1988) Gene73, 237-244). The propeptide is predicted to have a molecular weight of56,800 Daltons. Assuming cleavage of the signal peptide at position 18,the unmodified mature protein has a molecular weight of 54,724 Daltons.

The overall similarities between this protein and the other knownmembers of the triacylglycerol lipase family is illustrated in FIG. 6and Table 1. In the alignment shown in FIG. 6, LIPG is the polypeptide(SEQ ID NO: 6) encoded by the cDNA (SEQ ID NO: 5) described in Example1, and hereafter referred to as LLGN. This protein is identical with theLLGXL protein in the amino terminal 345 residues. Nine unique residuesare followed by a termination codon, producing a propolypeptide of 39.3kD and a mature protein of 37.3 kD. The sequences which are common toLLGN and LLGXL are nucleic acid sequence SEQ ID NO: 9 and amino acidsequence SEQ ID NO: 10.

Interestingly, the position at which the LLGN and LLGXL proteins divergeis at a region known from the structure of the other lipase to bebetween the amino and carboxy domains of the proteins. Therefore, theLLGN protein appears to consist of only one of the two domains oftriaclyglycerol lipases. This sequence contains the characteristic“GXSXG” lipase motif at positions 167-171 as well as conservation of thecatalytic triad residues at Ser 169, Asp 193, and His 274. Conservationof cysteine residues (positions 64, 77, 252, 272, 297, 308, 311, 316,463, and 483) which have been implicated in disulfide linkage in theother lipases suggests that the LLGXL protein has structuralsimilarities to the other enzymes. There are five predicted sites forN-linked glycosylation; at amino acid positions 80, 136, 393, 469, and491. The protein sequences used in the comparisons are human lipoproteinlipase (LPL; Genbank accession #M15856, SEQ ID NO: 13), Human hepaticlipase (HL; Genbank accession #J03540, SEQ ID NO: 14), human pancreaticlipase (PL; Genbank accession # M93285, SEQ ID NO: 15), human pancreaticlipase related protein-1 (PLRP-1; Genbank accession # M93283), and humanpancreatic lipase related protein-2 (PLRP-2; Genbank accession #M93284).

TABLE 1 Similarity of triacylglycerol lipase gene family LLGXL LPL HL PLPLRP1 PLRP2 LLGXL — 42.7 36.5 24.5 22.5 22.6 LPL 42.7 — 40.0 22.8 22.720.9 HL 36.5 40.0 — 22.8 24.0 22.0 PL 24.5 22.8 22.8 — 65.2 62.2 PLRP122.5 22.7 24.0 65.2 — 61.7 PRLP2 22.6 20.9 22.0 62.2 61.7 — Percentsimilarity was based on pairwise alignment using the Clustal algorithm(Camps, L., Reina, M., Llobera, M., Vilaro, S., and Olivecrona, T.(1990) Am. J. Physiol. 258, C673-C681) in the Megalign program of theLasergene Biocomputing Software Suite (Dnastar).

Chromosomal Localization

DNA from a P1 clone (Sternberg, N., Ruether, J. and DeRiel, K. The NewBiologist 2:151-62, 1990) containing genomic LLG DNA was labelled withdigoxigenin UTP by nick translation. Labelled probe was combined withsheared human DNA and hybridized to PHA stimulated peripheral bloodlymphocytes from a male donor in a solution containing 50% formamide,10% dextran sulfate, and 2×SSC. Specific hybridization signals weredetected by incubating the hybridized cells in fluoresceinatedantidigoxigenin antibodies followed by counterstaining with DAPI. Thisinitial experiment resulted in specific labeling of a group Echromosome, which was believed to be chromosome 18 on the basis of DAPIstaining.

A second experiment was conducted in which a biotin labelled probespecific for the centromere of chromosome 18 was cohybridized with theLLG probe. This experiment resulted in the specific labeling of thechromosome 18 centromere in red and the long arm of chromosome 18 ingreen. Measurements of 11 specifically labelled hybridized chromosomes18 demonstrated that LLG has a Flter of 0.67 (Franke measurement of0.38), which corresponds to band 18q21. Several genetic diseases,including intrahepatic cholestasis, cone rod dystrophy, and familialexpansile osteolysis, are believed to involve defects in thischromosomal region.

Example 3 LIPG RNA Analysis

Expression of LIPG RNA in THP-1 Cells

Analysis of the mRNA from which the cDNA was derived was performed bynorthern analysis of THP-1 RNA. RNA from these cells was prepared asdescribed above. The mRNA was purified from the total RNA through theuse of a poly-dT-magnetic bead system (Polyattract system, Promega).Three micrograms of poly (A)-containing mRNA was electrophoresed on a 1%agarose-formaldehyde gel. The gel was washed for 30 minutes in dH₂O.RNAs were vacuum transferred to a nylon membrane using alkaline transferbuffer (3M NaCl, 8 mM NaOH, 2 mM sarkosyl). After transfer, the blot wasneutralized by incubation for 5 minutes in 200 mM phosphate buffer pH6.8. The RNA was crosslinked to the membrane using an ultravioletcrosslinker apparatus (Stratagene).

A probe was made by excising the insert of a plasmid containing the5′RACE reaction PCR product described above. The probe was radiolabeledusing the random priming technique described in Example 2.

The filters were prehybridized in QuikHyb rapid hybridization solution(Stratagene) for 30 minutes at 65° C. The radiolabeled probe (1-2×10⁶cpm/ml) and sonicated salmon sperm DNA (final concentration 100 μg/ml)were denatured by heating to 95° C. for 10 minutes and quick-chilled onice before adding to the filter in QuikHyb. Hybridization was for 3hours at 65° C. The unhybridized probe was removed by washing thefilters two times for 15 minutes with 2×SSC, 0.1% sodium dodecyl sulfateat room temperature followed by two times for 15 minutes in 0.1×SSC,0.1% SDS at 62° C. Following the washes, the filters were allowed to drybriefly and then exposed to Kodak XAR-2 film with intensifying screensat −80° C. The results are shown in FIG. 7, which shows a major mRNAspecies of approximately 4.5 kilobases. Minor species of 4.3 and 1.6kilobases are also present. The expected size of the LLGN cDNA is 1.6kb. The LLGXL sequence is likely to be encoded by the major species ofmRNA detected.

Expression of LIPG RNA in Various Human Tissues

A commercially prepared filter containing 3 μg each of mRNAs from humantissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney,and pancreas) was obtained from Clontech (Catalog #7760-1). This filterwas probed and processed as described above. After probing with theradiolabeled LLG fragment and autoradiography, the probe was stripped bywashing in boiling 0.1×SSC, 0.1% SDS for 2×15 min. in a 65° C.incubator. The membranes were then probed with a 1.4 kilobase pair DNAfragment encoding human lipoprotein lipase. This fragment was obtainedby RT-PCR of the THP-1 RNA (PMA and oxLDL treated) using the 5′LPL and3′LPL primers described in FIG. 1. and the RT-PCR conditions describedabove. After autoradiography, the membranes were stripped again andreprobed with a radiolabeled fragment of the human beta actin cDNA tonormalize for RNA content. The results of these analyses are shown inFIG. 8. The highest levels of LIPG message were detected in placentalRNA, with lower levels found in RNAs derived from lung, liver, andkidney tissue. In agreement with previous studies by others (Verhoeven,A. J. M., Jansen, H. (1994) Biochem. Biophys. Acta 1211, 121-124),lipoprotein lipase message was found in many tissues, with highestlevels found in heart and skeletal muscle tissue. Results of thisanalysis indicates that the tissue distribution of LIPG expression isvery different from that of LPL. The pattern of LIPG expression is alsodifferent from that of either hepatic lipase or pancreatic lipase, asreported by others (Wang, C.-S., and Hartsuck, J. A. (1993) Biochem.Biophys. Acta 1166, 1-19; Semenkovich, C. F., Chen, S.-W., Wims, M., LuoC.-C., Li, W.-H., and Chan, L. (1989) J. Lipid Res. 30, 423-431; Adams,M. D., Kerlavage, A. R., Fields, C., and Venter, C. (1993) Nature Genet.4, 256-265).

To determine the expression pattern in additional human tissues, anothercommercially prepared membrane was probed with LLGXL cDNA. This dot blot(Human RNA Master Blot, Clontech Cat. #7770-1) contains 100-500 ng mRNAfrom 50 different tissues and is normalized for equivalent housekeepinggene expression (Chen, L., and Morin, R. (1971) Biochim. Biophys. Acta231, 194-197). A 1.6 kb DraI-SrfI fragment of the LLGXL cDNA was labeledwith ³²PdCTP using a random oligonucleotide priming system (Prime It II,Stratagene) according to the manufacturer's instructions. After 30minutes prehybridization at 65° C., the probe was added to QuikHybhybridization solution at 1.3×10⁶ cpm/ml. Hybridization was for 2 hoursat 65° C. The unhybridized probe was removed by washing the filters twotimes for 15 minutes with 2×SSC, 0.1% sodium dodecyl sulfate at roomtemperature followed by two times for 15 minutes in 0.1×SSC, 0.1% SDS at62° C. Following the washes, the filters were allowed to dry briefly andthen exposed to Kodak XAR-2 film with intensifying screens at −80° C.for varying amounts of time. The resulting images were quantitated bydensitometry. The results are shown in Table 2. The relative expressionlevels of tissues represented in both the multiple tissue northern andthe multiple tissue dot blot are similar, with highest levels inplacenta, and lower levels in lung, liver and kidney. Fetal liver,kidney, and lung also express roughly the same levels as the adulttissues. Surprisingly, thyroid tissue expression levels were the highestof all tissues represented, with expression of 122% of that in placentaltissue. While there is precedence for lipase expression by the placenta(Rothwell, J. E., Elphick, M. C. (1982) J. Dev. Physiol. 4, 153-159;Verhoeven, A. J. M., Carling D., and Jansen H. (1994) J. Lipid Res. 35,966-975; Burton, B. K., Mueller, H. W. (1980) Biochim. Biophys. Acta618, 449-460), the thyroid was not previously known to express anylipase. These results suggest that LIPG expression may be involved inmaintenance of the placenta, where LIPG may serve to liberate free fattyacids from substrates such as phospholipids as a source of energy. TheLIPG expressed in the thyroid may provide precursors for the synthesisof bioactive molecules by that gland.

TABLE 2 Expression of LIPG mRNA in various human tissues whole brainN.D. substantial N.D. uterus N.D. mammary N.D. lung  29 nigra glandamygdala N.D. temporal N.D. prostate  5 kidney 44 trachea  12 lobecaudate N.D. thalamus N.D. stomach N.D. liver 61 placenta 100 nucleuscerebellum 4 sub-thalamic N.D. testes  9 small  6 fetal brain  5 nucleusintestine cerebral N.D. spinal cord N.D. ovary N.D. spleen N.D. fetalheart N.D. cortex frontal lobe N.D. heart N.D. pancreas N.D. thymus N.D.fetal kidney  56 hippocampus N.D. aorta N.D. pituitary N.D. peripheralN.D. fetal liver  14 gland leukocyte medulla N.D. skeletal N.D. adrenalgland N.D. lymph node N.D. fetal spleen N.D. oblongata muscle occipitallobe N.D. colon 8 thyroid gland 122 bone marrow N.D. fetal thymus N.D.putamen N.D. bladder N.D. salivary N.D. appendix  7 fetal lung  8 glandValues given are percentage of expression with levels in placentaltissue arbitrarily set at 100%. Values are average of densitometricmeasurements from two autoradiographic exposures. N.D. =not detectable.

Expression of LIPG RNA in Cultured Endothelial Cells

Human umbilical vein endothelial cells (HUVEC) and human coronaryarterial endothelial cells (HCAEC) were obtained from Clonetics. HUVECswere propagated in a commercially prepared endothelial cell growthmedium (EGM, Clonetics) supplemented with 3 mg/ml bovine brain extract(Maciag, T., Cerundolo, J., Ilsley, S., Kelley, P. R., and Forand, R.(1979) Proc. Natl. Acad. Sci. USA 76, 5674-5678), Clonetics), whileHCAECs were propagated in EGM supplemented with 3 mg/ml bovine brainextract and 3% fetal bovine serum (5% final concentration). Cells weregrown to confluence, then the medium was changed to EGM without bovinebrain extract. Cultures were stimulated by adding 100 ng/ml of phorbolmyristate (Sigma). After 24 hours incubation, the RNAs were extractedfrom the cells via the Trizol method described above. Twenty microgramsof total RNA was electrophoresed and transferred to the membrane foranalysis. The membranes were probed with LIPG and LPL probes asdescribed above. The results are shown in FIG. 9. Twenty micrograms oftotal RNA from THP-1 cells stimulated with PMA was run on the blot forcomparison. RNA hybridizing to the LIPG probe was detected inunstimulated and PMA stimulated HUVEC cells. In contrast, detectablelevels of LIPG mRNA were only found in HCAEC cultures after stimulationwith PMA. In agreement with previous studies of others, no detectablelipoprotein lipase mRNA was detected in any of the endothelial RNAs(Verhoeven, A. J. M., Jansen, H. (1994) Biochem. Biophys. Acta 1211,121-124).

Example 4 LIPG Protein Analysis

Antibody Preparation

Antisera were generated to peptides with sequences corresponding to aregion of the predicted protein encoded by the LIPG cDNA open readingframe. This peptide was chosen because of its high predictedantigenicity index (Jameson B. A., and Wolf, H. (1988) Comput. Applic.in the Biosciences 4, 181-186). The sequence of the immunizing peptidewas not found in any protein or translated. DNA sequence in the Genbankdatabase. Its corresponding position in the LIPG protein is shown inFIG. 10. The carboxy terminal cysteine of the peptide does notcorrespond to the residue in the LIPG putative protein, but wasintroduced to facilitate coupling to the carrier protein. The peptidewas synthesized on a Applied Biosystems Model 433A peptide synthesizer.Two milligrams of peptide was coupled to two milligrams ofmaleimide-activated keyhole limpet hemocyanin following the protocolsincluded in the Imject Activated Immunogen Conjugation Kit (PierceChemical). After desalting, one-half of the conjugate was emulsifiedwith an equal volume of Freund's complete adjuvant (Pierce). Thisemulsification was injected into a New Zealand White rabbit. Four weeksafter the initial inoculation, a booster inoculation was made with anemulsification made exactly as described above except Freund'sincomplete adjuvant (Pierce) was used. Two weeks after the boost, a testbleed was made and titers of specific antibodies were determined viaELISA using immobilized peptide. A subsequent boost was made one monthafter the first boost.

Western Analysis of Medium from Endothelial Cell Cultures

HUVEC and HCEAC cells were cultured and stimulated with PMA as describedin Example 3C, except that the cells were stimulated with PMA for 48hours. Samples of conditioned medium (9 ml) were incubated with 500 μlof a 50% slurry of heparin-Sepharose CL-6B in phosphate buffered saline(PBS, 150 mM sodium chloride, 100 mM sodium phosphate, pH 7.2).Heparin-Sepharose was chosen to partially purify and concentrate theLIPG proteins because of the conservation of residues in the LLGXLsequence which have been identified as critical for the heparin-bindingactivity of LPL (Ma, Y., Henderson, H. E., Liu, M.-S., Zhang, H.,Forsythe, I. J., Clarke-Lewis, I., Hayden, M. R., and Brunzell, J. D. J.Lipid Res. 35, 2049-2059; and FIG. 6.). After rotation at 4° C. for 1hour, the samples were centrifuged for 5 minutes at 150×g. The mediumwas aspirated and the Sepharose was washed with 14 ml PBS. Aftercentrifugation and aspiration, the pelleted heparin-Sepharose wassuspended in 200 μl 2×SDS loading buffer (4% SDS, 20% glycerol, 2%β-mercaptoethanol, 0.002% bromphenol blue, and 120 mM Tris pH 6.8). Thesamples were heated to 95° C. for 5 minutes and 40 μl was loaded onto a10% Tris-Glycine SDS gel. After electrophoresis at 140 V forapproximately 90 minutes, the proteins were transferred tonitrocellulose membranes via a Novex electroblotting apparatus (210 V, 1hour). The membranes were blocked for 30 minutes in blocking buffer (5%nonfat dried milk, 0.1% Tween 20, 150 mM sodium chloride, 25 mM Tris pH7.2). Antipeptide antisera and normal rabbit serum was diluted 1:5000 inblocking buffer and was incubated with the membranes overnight at 4° C.with gentle agitation. The membranes were then washed 4×15 minutes withTBST (0.1% Tween 20, 150 mM sodium chloride, 25 mM Tris pH 7.2). Goatanti-rabbit peroxidase conjugated antisera (Boehringer Mannheim) wasdiluted 1:5000 in blocking buffer and incubated with the membrane for 1hour with agitation. The membranes were washed as above, reacted withRenaissance chemiluminescent reagent (DuPont NEN), and exposed to KodakXAR-2 film. The results are shown in FIG. 11. Two species ofimmunoreactive proteins are present in the samples from unstimulatedHUVEC and HCAEC cells. Levels of immunoreactive protein in theunstimulated HCAEC samples are much lower than the corresponding HUVECsample. Upon stimulation with PMA, three immunoreactive proteins aresecreted by the endothelial cell cultures. PMA exposure greatlyincreased the level of LIPG proteins produced by the HCAEC cultures. PMAinduction of LLG proteins was not as dramatic in the HUVEC cultures.

Example 5 Recombinant LIPG Protein Production

LIPG Expression Constructs

The cDNAs encoding the LLGN and LLGXL proteins were cloned into themammalian expression vector pcDNA3 (Invitrogen). This vector allowsexpression of foreign genes in many mammalian cells through the use ofthe cytomegalovirus major late promoter. The LLGN 5′RACE product wascloned into the EcoRI site of pcDNA3. The LLGXL cDNA was digested withDraI and SrfI to yield a 1.55 kb cDNA (see FIG. 4.). The vector wasdigested with the restriction enzyme EcoRV and the vector and insertwere ligated using T4 DNA ligase and reagents from the Rapid LigationKit (Boehringer Mannheim) according to the manufacturers instructions.The ligation products were used to transform competent E. coli.Resultant colonies were screened by restriction analysis and sequencingfor the presence and orientation of the insert in the expression vector.

Transient Transfection of LIPG in COS-7 Cells

The LIPG expression vectors were introduced into COS-7 cells through theuse of Lipofectamine cationic lipid reagent (GIBCO). Twenty-four hoursbefore the transfection, COS-7 cells were plated onto 60 mm tissueculture dishes at a density of 2×10⁵ cells/plate. The cells werepropagated in Dulbecco's modified Eagle's medium (DMEM; GIBCO)supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 μg/mlstreptomycin. One microgram of plasmid DNA was added to 300 μl ofOptimem I serum-free medium (Gibco). Ten microliters of Lipofectaminereagent were diluted into 300 μl of Optimem I medium and this wascombined with the DNA solution and allowed to sit at room temperaturefor 30 minutes. The medium was removed from the plates and the cellswere rinsed with 2 ml of Optimem medium. The DNA-Lipofectamine solutionwas added to the plates along with 2.7 ml Optimem medium and the plateswere incubated for 5 hours at 37° C. After the incubation, the serumfree medium was removed and replaced with DMEM supplemented with 2% FBSand antibiotics. Twelve hours post-transfection, some of the cultureswere treated with either 0.25 mM Pefabloc SC (Boehringer Mannheim), aprotease inhibitor, or 10 U/ml heparin. Thirty minutes before harvest,the heparin treated samples were treated with an additional 40 U/mlheparin. The medium was removed from the cells 60 hours aftertransfection. Heparin-Sepharose CL-4B (200 μl of a 50% slurry in PBS pH7.2) was added to 1 ml of medium and was mixed at 4° C. for 1 hour. TheSepharose was pelleted by low speed centrifugation and was washed threetimes with 1 ml cold PBS. The Sepharose was pelleted and suspended in100 μl 2× loading buffer. The samples were heated to 95° C. for 5minutes. 40 μl of each sample was loaded onto a 10% SDS-PAGE gel.Electrophoresis and western analysis was performed using the anti-LIPGantiserum as described above. The results are shown in FIG. 12. Proteinsfrom HCAEC conditioned medium were included for size references. LLGNmigrates at approximately 40 kD, corresponding to the lowest band inHCAEC. The medium from COS cells transfected with LLGXL cDNA containsboth 68 kD and 40 kD species. When these cells were treated withheparin, the amount of both 68 kD and 40 kD proteins recovered from themedium increased dramatically, indicating either the release ofproteoglycan-bound protein from the cell surface or stabilization of theproteins by heparin. When the cells were treated with the proteaseinhibitor Pefabloc, the amount of 68 kD protein increased relative tothat of the 40 kD species. This suggests that the lower molecular weightprotein produced by these cells is a proteolysis product of the larger68 kD form. The role of the mRNA identified through differential displaywhich encodes a shorter, 40 kD species is not known. There has, however,been a report of an alternately-spliced form of hepatic lipase whichapparently is expressed in a tissue-specific manner and would create atruncated protein.

Example 6 LIPG in Animal Species

Cloning the Rabbit Homolog of LIPG

A commercially available lambda cDNA library derived from rabbit lungtissue (Clontech, Cat. #TL1010b) was used to isolate a fragment of therabbit homolog of the LIPG gene. Five microliters of the stock librarywere added to 45 μl water and heated to 95° C. for 10 minutes. Thefollowing were added in a final volume of 100 μl: 200 μM dNTPs, 20 mMTris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl₂, 100 μM each primer DLIP774 andLLGgen2a, and 2.5 U Taq polymerase (GIBCO). The reaction wasthermocycled 35 times with the parameters of: 15 seconds at 94° C., 20seconds at 50° C. and 30 seconds at 72° C. Ten microliters of thereaction was analyzed via agarose gel electrophoresis. A product ofapproximately 300 basepairs was detected. A portion (4 μl) of thereaction mix was used to clone the product via the TA cloning system.The insert of a resulting clone was sequenced (SEQ ID NO: 11). Analignment between the deduced rabbit amino acid sequence (SEQ ID NO: 12)and the corresponding sequence of the human cDNA is also shown in FIG.14. Of the nucleotides not part of either amplification primer, there isan 85.8% identity between the rabbit and human LLG sequences. Thepredicted protein encoded by this rabbit cDNA shares 94.6% identity withthat of the human protein, with most of the nucleotide substitutions inthe third or “wobble” positions of the codons. Notably, this regionspans the “lid” sequence of the predicted LLG proteins and is a variabledomain in the lipase gene family. This is evidence that there is a highdegree of conservation of this gene between species.

LIPG in Other Species

To demonstrate the presence of LLG genes in other species, genomic DNAsfrom various species were restriction digested with EcoRI, separated byelectrophoresis in agarose gels, and blotted onto nitrocellulosemembranes.

The membranes were hybridized overnight at 65° C. with 2.5×10⁶ cpm/ml ofrandom primed ³²P-LLG or ³² P-LPL (lipoprotein lipase) probe in ahybridization solution of 6×SSC, 10% dextran sulfate, 5×Dendardt'ssolution, 1% SDS, and 5 μg/ml salmon sperm DNA. The membranes werewashed with 0.1×SSC, 0.5% SDS for ten minutes at room temperature, thensequentially for ten minutes at 40° C., 50° C., and 55° C.Autoradiograms of the blots are shown in FIG. 16.

FIG. 16 shows the presence of LLG and LPL genes in all species examined,with the exception that no hybridization was observed with the LLG probeagainst rat DNA. The exceptional data from rat may represent an artifactcaused by generation of abnormally sized restriction fragmentscontaining LLG sequences. Such fragments may be outside of thefractionation range of the agarose gel or may blot inefficiently. Thedifferent bands detected by the two probes indicate that LPL and LIPGare separate, evolutionarily conserved genes.

Example 7 Enzymatic Activity of LLGXL

Phospholipase Activity

Conditioned media from COS-7 cells transiently expressing humanlipoprotein lipase (LPL), LLGN, or LLGXL were assayed for phospholipaseactivity. MEM containing 10% FBS (MEM) was used as the blank, andconditioned media from COS-7 cells transfected with an antisense LLGXLplasmid (AS) was used as a negative control.

A phosphatidylcholine (PC) emulsion was made up using 10 μlphosphatidylcholine (10 mM), 40 μl ¹⁴C-phosphatidylcholine, dipalmitoyl(2 μCi), labeled at the sn 1 and 2 positions, and 100 μl Tris-TCNB [100mM Tris, 1% Triton, 5 mM CaCl₂, 200 mM NaCl, 0.1% BSA). The emulsion wasevaporated for 10 minutes, then brought to a final volume of 1 ml inTris-TCNB.

Reactions were performed in duplicate and contained 50 μl PC emulsionand 950 μl medium. Samples were incubated in a shaking water bath for2-4 hours at 37° C. The reactions were terminated by adding 1 ml 1N HCl,then extracted with 4 ml of 2-propanol:hexane (1:1). The upper 1.8 mlhexane layer was passed through a silica gel column, and the liberated¹⁴C-free fatty acids contained in the flow-thru fraction werequantitated in a scintillation counter. The results of these assays areshown in FIG. 14.

Triacylglycerol Lipase Activity

Conditioned media from COS-7 cells transiently expressing humanlipoprotein lipase (LPL), LLGN, or LLGXL were assayed for triglycerollipase activity. MEM containing 10% FBS was used as the blank, andconditioned media from COS-7 cells transfected with an antisense LLGXLplasmid (AS) was used as a negative control.

A concentrated substrate was prepared as an anhydrous emulsion oflabeled triolein, [9,10-³H(N)] and unlabeled triolein (final totaltriolein=150 mg with 6.25×10⁸ cpm), which was stabilized by adding 9 mgof lecithin in 100% glycerol. 0.56 ml of ³H-triolein, (0.28 mCi) wasmixed with 0.17 ml of unlabeled triolein and 90 μl of lecithin (9 mg).The mixture was evaporated under a stream of nitrogen. The dried lipidmixture was emulsified in 2.5 ml 100% glycerol by sonication (30 secondpulse level 2 followed by 2 second chill cycles over 5 minutes].

The assay substrate was prepared by dilution of 1 volume of concentratedsubstrate with 4 volumes of 0.2M Tris-HCl buffer (pH 8.0) containing 3%w/v fatty acid free bovine serum albumin. The diluted substrate wasvortexed vigorously for 5 seconds.

Reactions were performed in duplicate in a total volume of 0.2 mlcontaining 0.1 ml of assay substrate and 0.1 ml of the indicatedconditioned media. The reactions were incubated for 90 minutes at 37° C.The reactions were terminated by adding 3.25 ml ofmethanol-chloroform-heptane 1.41:1.25:1 (v/v/v) followed by 1.05 ml of0.1M potassium carbonate-borate buffer (pH 10.5). After vigorous mixingfor 15 seconds, the samples were centrifuged for 5 minutes at 1000 rpm.A 1.0 ml aliquot of the upper aqueous phase was counted in ascintillation counter. The results of these assays are shown in FIG. 15.

Example 8 Use of LIPG Polypeptide to Screen for Enhancers or Inhibitors

Recombinant LIPG is produced in baculovirus-infected insect cells orstably transfected CHO cells or other acceptable mammalian host cells.Recombinant LIPG is purified from the serum-containing or serum-freeconditioned medium by chromatography on heparin-Sepharose, followed bychromatography on a cation exchange resin. A third chromatographic orfurther chromatographic steps, such as molecular sieving, is used in thepurification of LIPG if needed. During purification, anti-peptideantibodies are used to monitor LIPG protein and the phospholipase assayis used to follow LIPG activity.

In the fluorescent assay, the final assay conditions are approximately10 mM Tris-HCl (pH 7.4), 100 mM KCl, 2 mM CaCl₂, 5 μMC₆NBD-PC{1-acyl-2-[6-(nitro-2,1,3-benzoxadiazol-4-yl)amino]caproylphosphatidylcholine,and LIPG protein (approx. 1-100 ng). The reaction is subjected tofluorescence excitation at 470 nm, and enzyme activity, as measured bythe fluorescence emission at 540 nm is continuously monitored. Compoundsand/or substances to be tested for stimulation and/or inhibition of LIPGactivity are added as 10-200 mM solutions in dimethylsulfoxide.Compounds which stimulate or inhibit LIPG activity are identified ascausing an increased or decreased fluorescence emission at 540 nm.

In the thio assay, the final assay conditions are approximately 25 mMTris-HCl (pH 8.5), 100 mM KCl, 10 mM CaCl₂, 4.24 mM Triton X-100, 0.5 mM1,2-bis(hexanoylthio)-1,2-dideoxy-sn-glycero-3-phosphorylcholine, 5 mM4,4′-dithiobispyridine (from a 50 mM stock solution in ethanol), and1-100 ng recombinant LIPG. Phospholipase activity is determined bymeasuring the increase in absorption at 342 nm. Compounds and/orsubstances to be tested for stimulation and/or inhibition of LIPGactivity are added as 10-200 mM solutions in dimethylsulfoxide.Compounds which stimulate or inhibit LIPG activity are identified ascausing an increased or decreased absorption at 342 nm.

Example 9 Transgenic Mice Expressing Human LIPG

To further study the physiological role of LIPG, transgenic miceexpressing human LIPG are generated.

The 1.53 kb DraI/SrfI restriction fragment encoding LLGXL (see FIG. 4)was cloned into a plasmid vector (pHMG) downstream of the promoter forthe ubiquitously expressed 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase gene. Transgenic mice expressing different levels ofhuman LLGXL are generated using standard methods (see, e.g., G. L. Trompet al. Gene 1565:199-205, 1995). The transgenic mice are used todetermine the impact of LLGXL overexpression on lipid profile, vascularpathology, rate of development and severity of atherosclerosis, andother physiological parameters.

Example 10 Expression of LIPG in Atherosclerotic Tissues

LLGXL expression in atherosclerosis was examined by performing a reversetranscription-polymerase chain reaction (RT-PCR) using mRNA isolatedfrom vascular biopsies from four patients with atherosclerosis. Thetissue samples were from the aortic wall (one sample), the iliac artery(two samples), and the carotid artery (one sample).

Atherosclerosis biopsies were received from Gloucestershire RoyalHospital, England, and polyA+ mRNA was prepared and resuspended indiethylpyrocarbonate (DEPC) treated water at a concentration of 0.5μg/μl mRNA. Reverse transcriptase reactions were performed according tothe GibcoBRL protocol for Superscript Preamplification System for FirstStrand cDNA Synthesis. Briefly, the cDNA was synthesized as follows: 2μl of each mRNA was added to 1 μl oligo (dT)₁₂₋₁₈ primer and 9 μl ofDEPC water. The tubes were incubated at 70° C. for 10 minutes and put onice for 1 minute. To each tube, the following components were added: 2μl 10×PCR buffer, 2 μl 25 mM MgCl₂, 1 μl 10 mM dNTP mix and 2 μl 0.1MDTT. After 5 minutes at 42° C., 1 μl (200 units) of Super Script IIreverse transcriptase was added. The reactions were mixed gently, thenincubated at 42° C. for 50 minutes. The reactions were terminated byincubation at 70° C. for 15 minutes then put on ice. The remaining mRNAwas destroyed by the addition of 1 μl of RNase H to each tube andincubated for 20 minutes at 37° C.

PCR amplifications were performed using 2 μl of the cDNA reactions. Toeach tube the following were added: 5 μl 10×PCR buffer, 5 μl 2 mM dNTPs,1 μl hllg-gsp1 primer (20 pmol/ml, see FIG. 1), 1 μl hllg-gsp2a primer(20 pmol/ml, see FIG. 1), 1.5 μl 50 mM MgCl₂, 0.5 μl Taq polymerase (5U/ml) and 34 μl water. After holding the reactions at 95° C. for 2minutes, thirty cycles of PCR were performed as follows: 15 seconds at94° C., 20 seconds at 52° C., and 30 seconds at 72° C. The finishedreactions were held for 10 minutes at 72° C. before analysis by agarosegel electrophoresis. The hllg-gsp primers are specific for LIPG andyield an expected product of 300 bp. In a parallel PCR to show that thecDNA synthesis reactions had been successful, primers specific for thehousekeeping gene, G3PDH (human glyceraldehyde 3-phosphatedehydrogenase) were used (1 μl each at 20 pmol/ml).

The G3PDH primers (see FIG. 1) yielded the expected product of 983 bp inall four vascular biopsy samples. LIPG expression was detected in threeof the four samples, with no expression being detected in the carotidartery sample.

Example 11 Differential Display, RT-PCR and cDNA Library Screening

To perform the experiments discussed in Examples 12 to 16, the followingprocedure (based on the procedure outlined in Example 1) was used toobtain the cDNA for LIPG. THP-1 cells were plated in the presence ofphorbol 12-myristate 13-acetate (PMA, 40 ng/ml; Sigma) for 48 hours. Thedifferentiated THP-1 cells were exposed for 24 hours to either oxLDL (50μg/ml) or control medium. Total RNAs were collected and purified usingstandard procedures. Poly(A)⁺ RNA was purified from total RNA using apoly-dT magnetic bead system (Promega). cDNA synthesis and PCRamplification were accomplished using protocols from the DifferentialDisplay kit, version 1.0 (Display Systems Biotechnology). The primerpairs that yielded the initial cDNA fragment of EL were downstreamprimer 7 (5′-TTTTTTTTTTTGA-3′) and upstream primer 15(5′-GATCCAATCGC-3′). The amplification reaction was fractionated on a 6%nondenaturing acrylamide sequencing format gel and an amplificationproduct found only in the reaction containing cDNA from THP-1 cellsexposed to oxLDL was identified and excised from the gel. Areamplification using the same primers was performed and the product wasexcised and subcloned into the pCRII vector using the TA cloning system(Invitrogen). Insert sizes were determined using EcoRI digestions of theplasmids, and clones containing inserts of the approximate size of theoriginal PCR product were sequenced using fluorescent dye-terminatorreagents (Prism, Applied Biosystems) and an Applied Biosystems 373 DNAsequencer. We extended the cDNA sequence of the original, gel-excisedcDNA using the 5′-RACE system (GIBCO). RNA (1 μg) from the THP-1 cellsused initially in the differential display reactions was used in the5′-RACE procedure using a gene-specific primer(5′-TAGGACATGCACAGTGTAATCTG-3′) for first strand cDNA synthesis. Weperformed PCR amplification of the cDNA using an anchor primer andgene-specific primer 2 (5′-GATTGTGCTGGCCACTTCTC-3′). This reaction (1μl) was used in a nested re-amplification using the universalamplification primer (5′-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3′) and thegene-specific primer 3 (5′-GACACTCCAGGGACTGAAG-3′) to increase levels ofspecific product for subsequent isolation. The reaction products werecloned into the pCRII vector from the TA cloning kit and determined thesequence. A human placental cDNA library (oligo dT and random primed)was obtained from Clontech and probed with the 5′-RACE reaction PCRproduct. The DNA from hybridizing clones was purified using LambdaSorbreagent (Promega). Inserts were excised from the phage DNA by digestionwith EcoRI, subcloned into the EcoRI site of the Bluescript II SKplasmid vector (Stratagene) and sequenced.

Example 12 Antibody Preparation

A 17-residue peptide (GPEGRLEDKLHKPKATC) was synthesized correspondingto residues 8-23 of the secreted LIPG gene product on a Model 433Apeptide synthesizer (Applied Biosystems). Peptide (2 mg) was coupled tomaleimide-activated keyhole limpet haemocyanin (2 mg) following theprotocols included in the Imject Activated Immunogen Conjugation kit(Pierce Chemical). After desalting, one-half of the conjugate wasemulsified with an equal volume of Freund's complete adjuvant (Pierce)and injected into a New Zealand White rabbit. Four weeks after theinitial inoculation, a booster inoculation was administered with anemulsification made exactly as described above except for the use ofFreund's incomplete adjuvant (Pierce). Two weeks after the boost, thetitres of specific antibodies were determined in a test bleed via ELISAusing immobilized peptide.

Example 13 Gene Expression Studies

HUVECs were propagated in a commercially prepared endothelial cellgrowth medium (EGM, Clonetics) supplemented with bovine brain extract (3mg/ml; Clonetics), whereas HCAECs were propagated in EGM with bovinegrain extract (3 mg/ml) and 5% fetal bovine serum. Cultures werestimulated by addition of PMA (100 ng/ml). After 24 hours incubation,RNA was extracted from the cells via the Trizol method, electrophoresedon a 1% agarose-formaldehyde gel, transferred to Nytran membrane on aTurboblotter apparatus (Schleicher and Schuell) and crosslinked to themembrane using a Stratalinker ultraviolet crosslinker (Stratagene). The5′-RACE reaction PCR product was radiolabelled using the random primingtechnique. The radiolabelled probe (1−2×10⁶ cpm/ml) was denatured byheating to 95° C. for 10 minutes and quick-chilled on ice before addingto the filter in QuikHyb. Hybridization was allowed to proceed for 3hours at 65° C. Filters were exposed to Kodak XAR-2 film withintensifying screens at −80° C. We incubated HUVEC- andHCEAC-conditioned medium with heparin-Sepharose CL-6B at 4° C. for 1hour. After centrifugation, the pelleted heparin-Sepharose was suspendedin SDS loading buffer, heated to 95° C. for 5 minutes and loaded onto a10% Tris-Glycine SDS gel (NOVEX). After electrophoresis at 140 V for 90minutes, the proteins were transferred to nitrocellulose membranes anddetected with rabbit anti-LIPG peptide antisera (1:5,000), with goatanti-rabbit peroxidase conjugated antisera (1:5,000; Boehringer) as thesecondary antibody. The membranes were reacted with Renaissancechemiluminescent reagent (DuPont NEN) and exposed to Kodak XAR-2 film. Acommercially prepared filter containing poly(A)⁺ RNAs (3 μg each) fromhuman heart, brain, placenta, lung, liver, skeletal muscle, kidney andpancreas (Clontech) was hybridized with a radiolabelled fragment andprocessed as described above. Following autoradiography, the blot wasstripped by washing in boiling 0.1×SSC, 0.1% SDS for 2×15 minutes at 65°C. and then probed as described above with a 1.4-kb cDNA fragment,encoding human LPL. This fragment was obtained by RT-PCR of the THP-1RNA (PMA and oxLDL treated) using the 5′ LPL and 3′ LPL primers5′-ACCACCATGGAGAGCAAAGCCCTG-3′ and 5′-CCAGTTTCAGCCTGACTTCTTATTC-3′,respectively. After exposure to film, the membranes were stripped againand reprobed with a radiolabelled fragment of human β actin cDNA tonormalize to RNA content.

Human umbilical vein endothelial cells (HUVEC) were negative for LPLmRNA expression as expected, but were found to constitutively express ahigh level of mRNA for the LIPG gene (FIG. 9).

Human coronary artery endothelial cells (HCAEC) were also found toexpress the mRNA which was further upregulated on treatment of thesecells with phorbol ester (FIG. 9).

Conditional medium from stimulated HUVEC and HCAEC containedimmunoreactive proteins of approximately 68 kD and 40 kD, as well as aless prominent band of 55 kD (FIG. 11).

To determine the tissue sites of LIPG production in vivo, a multiplehuman tissue northern blot analysis with probes for both LIPG and LPLwas performed. Abundant levels of LIPG mRNA were found in lung, liverand kidney (FIG. 8) tissues, which showed low levels of LPL expression.LIPG was also expressed at high levels in the placenta (FIG. 8),suggesting the potential for a role in development.

In tissues such as heart and skeletal muscle, which expressed thehighest amount of LPL (confirming previous reports, Goldberg, J. I., J.Lipid Res., 37, 693-707 (1996)), we did not detect LIPG expression. Thisanalysis indicated that the tissue distribution of LIPG expression isvery different from that of LPL, as well as that reported for HL and PL.We found no LIPG mRNA in adrenals or ovaries, but did find a very lowlevel of LIPG mRNA in the testes (data not shown). We also found thatHepG2 cells express LIPG mRNA and protein in vitro (data not shown), butat levels less than 10% of that expressed by HUVECs.

Example 14 Lipase Assays

The cDNA and the 1.4-kb LPL cDNA were cloned into the EcoRV site of themammalian expression vector pcDNA3 (Invitrogen). An antisense pcDNA3vector was used as negative control. The recombinant expression vectors(3 μg) were mixed with lipofectamine (Life Technologies) and transfectedin quadruplicate into semiconfluent COS7 cells in 60-mm dishes.Established methods were used to assay samples of conditioned media fromtransfected COST cells for TG lipase and phospholipase activities(Goldberg, J. I., J. Lipid Res., 37, 693-707 (1996)). for the TG lipaseassay, 9,10-³H(N)-triolein (250 μCi; NEN) was mixed with unlabeledtriolein (150 mg) and type IV-S-α lecithin (9 mg; Sigma) in glycerol.The mixture was evaporated under nitrogen and emulsified in glycerol(2.5 ml) by sonication with a Branson Sonifier 450. The assay substratewas prepared by combining one volume of the emulsified substrate, fourvolumes of Tris-HCl (0.2 M, pH 8.0) containing 3% (w/v) fatty acid-freebovine serum albumin (BSA) and one volume of heat-inactivated bovineserum. Reactions were performed in triplicate in a total volume (0.2 ml)containing assay substrate (0.1 ml) and conditioned media (0.1 ml). Thereactions were incubated for 2 hours at 37° C. and terminated by addingmethanol-chloroform-heptane (1.41:1.25:1; 3.25 ml) followed by potassiumcarbonate-borate buffer (1.05 ml; 0.1 M, pH 10.5). After vigorous mixingfor 15 seconds, the samples were centrifuged for 5 minutes at 1,000 rpmand the upper aqueous phase (1.0 ml) was counted in a scintillationcounter. For the phospholipase assay, a phosphatidylcholine (PC)emulsion was made by combining ¹⁴C-dipalmitoyl PC (2 μCi; NEN) andlecithin (10 μl) with Tris-TCNB (100 μl; 100 mM Tris-HCl pH 7.4, 1%Triton X-100, 5 mM CaCl₂, 200 mM NaCl, 0.1% BSA). The mixture wasvortexed for 2 minutes and then evaporated under nitrogen. The driedlipid was reconstituted with TCNB (1 ml) and vortexed for 10 seconds.Reactions were performed in triplicate and contained PC emulsion (50μl), conditioned media (600 μl) and MEM (350 μl). Samples were incubatedat 37° C. for 2 hours, terminated by addition of HCl (1 ml) andextracted with 2-propanol:hexane (1:1; 4 ml). A sample (1.8 ml) of theupper hexane layer was passed through a silica gel column, and theliberated ¹⁴C-free fatty acids contained in the flow-through fractionwere quantitated in a scintillation counter. For both assays, MEMcontaining 10% FBS was used as a blank and conditioned media from COS7cells transfected with an antisense plasmid (AS) was used as a negativecontrol.

Example 15 Recombinant Adenovirus Construction and Animal Studies

A recombinant adenovirus encoding human LIPG was constructed asdescribed (Tsukamoto et al., J. Clin. Invest., 100, 107-114 (1997);Tsukamoto et al., J. Lipid Res., 38, 1869-1876 (1997)). In brief, thefull-length human cDNA was subcloned into the shuttle plasmid vectorpAdCMVLink1. After screening for the appropriate orientation byrestriction analysis, the plasmid was linearized with NheI andcotransfected into 293 cells along with adenoviral DNA digested withClaI. Cells were overlaid with agar and incubated at 37° C. for 15 days.Six plaques were picked and screened by PCR; two plaques positive forcDNA were subjected to a second round of plaque purification. Afterconfirmation of the presence of cDNA, the recombinant adenovirus wasexpanded in 293 cells at 37° C. Cell lysates were used to infect HeLacells for confirmation of the expression of human LIPG by western blotof conditioned media. The recombinant adenovirus (AdhEL) was furtherexpanded in 293 cells and purified by cesium chlorideultracentrifugation. Control adenovirus containing no cDNA insert(Adnull) was also subjected to plaque purification and purified asdescribed above. The purified viruses were stored in 10% glycerol/PBX at−80° C. Wild-type C57BL/6, human apoA-I transgenic and LDL receptormutant mice were obtained from Jackson Laboratory. All mice were fedchow diets. Wild-type and human apoA-I transgenic mice were injectedintravenously via the tail vein with AdhEL or Adnull 1×10¹¹ particles(approximately 2×10⁹ pfu) and LDLR-deficient mice were injected with1×10¹⁰ particles. In all experiments, blood was obtained from theretro-orbital plexus 1 day before injection and at multiple time pointsfollowing injection.

Intravenous injection of AdhEL into wild-type C57BL/6 mice resulted inexpression in the liver (FIG. 17) and reduction of plasma levels of HDLcholesterol that remained significantly lower than controlvirus-injected mice through at least 41 days post-injection (FIG. 18).Lipoproteins were separated by FPLC gel filtration, demonstrating thatHDL was undetectable 14 days after adenovirus injection (FIG. 19).Injection of recombinant LIPG adenovirus into human apoA-I transgenicmice (which have much higher levels of HDL cholesterol and apoA-I)reduced both HDL cholesterol (FIG. 20) and apoA-I (FIG. 21) levels. Todetermine the relative effects of LIPG expression on HDL compared withthe apoB-containing lipoproteins VLDL and LDL, we injected a lower doseof the LIPG adenovirus into chow-fed LDL receptor-deficient mice, whichhave approximately 70% of cholesterol in VLDL/LDL and approximately 30%in HDL. As before, expression of LIPG reduced HDL cholesterol levels(FIG. 23). Although LIPG expression reduced VLDL/LDL cholesterol levelsin the same mice (FIG. 24), the effect was proportionately less.Overexpression of LIPG reduced VLDL/LDL cholesterol, therefore a role ofLIPG in the modulation of apoB-containing lipoproteins cannot beexcluded.

Example 16 Lipid/Lipoprotein Analyses

The plasma total cholesterol and HDL cholesterol levels were measuredenzymatically on a Cobas Fara (Roche Diagnostic Systems) using Sigmareagents. ApoA-I was quantitated using a turbidometric assay (Sigma) ona Cobas Fara. Pooled plasma samples were subjected to fast proteinliquid chromatography (FPLC) gel filtration (Pharmacia LKBBiotechnology) using two Superose 6 columns in series as described(Tsukamoto et al., J. Clin. Invest., supra). Fractions (0.5 ml) werecollected, and cholesterol concentrations were determined using anenzymatic assay (Wako Pure Chemical Industries).

Example 17 Identification of Inhibitors of LIPG

Modulators of EL activity may be found using the following method:

Recombinant LIPG would be purified from the conditioned medium of stablytransfected Chinese hamster ovary cells, from baculovirus infectedinsect cells, yeast (Pichia pastoris, Kluveromyces Lactis) or othersources. Non-recombinant sources of LIPG (such as human plasma,endothelial cell conditioned media, etc.) could also be employed. Anexample of a primary screen to look for modulators of LIPG activitywould utilize the soluble fluorescent substrate 4-methylumberiferylhepatanoate. This assay is continuous and homogeneous. Hydrolysis ofthis substrate by LIPG results in the production of highly fluorescent4-methylumbelliferone that can be measured in a microplate fluorimeter.Other primary screening assay formats that could be used are ascintillation proximity assay (Amersham) that measures phospholipaseactivity, the lower-throughput radiometric phospholipase assay describedin Example 7 (and proposed below as a secondary assay), or thealternative phospholipase assays described in Example 8.

The catalytic center of LIPG, like other TG lipases, consists of thesame catalytic triad (ser, his, asp) found in serine proteases. Indeed,other TG lipases, such as lipoprotein lipase, are inhibited by serineprotease inhibitors such as PMSF and DFP. Either one of these compoundsmay serve as a positive control for inhibitors of LIPG activity.

Secondary Assay:

Compounds active in the esterase assay or alternative screening assaysdescribed above will be assayed in a standard, radiometric phospholipaseA assay. This assay measures the release of radiolabelled palmitic acidfrom mixed micelles containing [14C]-dipalmitoyl-phosphatidylcholine.Other assay formats could be envisioned which utilize fluorescentsubstrates and which would be amenable to a greater throughput.

Selectivity Assays:

Compounds would be assayed for inhibition of the related enzymeslipoprotein lipase (LPL) and pancreatic lipase (PL). Human PL and bovineLPL are commercially available and assays could be readily implemented.The phospholipase activity of PL is measured in exactly the same way asdescribed above for the secondary assay of LIPG. Since LPL is primarilya TG lipase, the secondary assay would measure radiolabelled fatty acid(oleic acid) release from a radiolabelled TG (triolein) substrate(described in Example 7). This assay has a similar capacity and may beadapted to other assay formats which utilize fluorescent substrates andwhich would be amenable to a greater throughput.

Phospholipase activity of LIPG would be tested on its in vivo substrate,HDL, in an in vitro assay. Radiolabelled HDL could be generated byexchange with a radiolabelled phospholipid, and then used to measureLIPG phosphospholipase activity and the activity of compounds emergingfrom the screens.

An additional assay could measure the impact of preincubation of LIPG,HDL, +/− compounds on radiolabelled cholesterol efflux from culturedcells such as the rat Fu5AH hepatoma line.

In vivo assays for assessment of compounds can be run in wild-type,LIPG-overexpressing, and as control, LIPG null mice. If, as in the caseof adenoEL expression, the transgenic mice exhibit decreased HDLrelative to control mice, then treatment of transgenic mice with LIPGinhibitory compounds would be expected to raise HDL to the levels ofcontrol mice. It is also possible that compounds could be tested fortheir LIPG inhibitory activity (elevation of HDL) in other animals suchas the LDLR−/− mouse, apoA1 transgenic mice hamsters, or rabbits.Compounds which elevated LIPG or LIPG activity would be expected toraise HDL in these or other animal models.

Example 18 Inhibitory Small Molecule Treatment Method

A small molecule (hereafter an “inhibitory small molecule”) identifiedin the screening outlined in Example 17 as able to inhibit the LIPGpolypeptide in vitro is tested for its ability to inhibit the LIPGpolypeptide in vivo. Wild-type and LIPG transgenic mice will be studiedby administering the small molecule orally (if orally bioavailable) orby intravenous injection. Activity of the LIPG polypeptide will bemeasured in plasma before and after heparin injection (to release theenzyme from bound sites). In addition, cholesterol, VLDL, LDL and HDLcholesterol and apoA-I levels will be monitored in animals receiving theinhibitory small molecule. Finally, LDL receptor deficient mice will befed an atherogenic diet and administered the inhibitory small moleculeor placebo for a period of 8 weeks. Atherosclerosis will be quantitatedin the aortas of the mice in order to determine whether administrationof the inhibitory small molecule recudes the progression or inducesregression of atherosclerosis. Based on these preclinical data,additional animal models such as hamsters, rabbits; or pigs will bestudied for the ability of the inhibitory small molecule to raise HDLcholesterol levels, reduce VLDL and LDL cholesterol levels, and/orinhibit the progression of atherosclerosis.

Those inhibitory small molecules found to have the desired propertieswill be administered to patients in combination with pharmaceuticallyacceptable carriers. The inhibitory small molecules may be administeredin a variety of ways, including oral administration and intravenousinjection. The patients' HDL, VLDL and LDL cholesterol levels will bemonitored to determine efficacy of the inhibitory small molecule and tooptimize dosage and administration protocols.

Example 19 Inhibitory Peptide Treatment Method

Therapeutic peptides are identified by testing fragments of the LIPGpolypeptide to determine which of these fragments inhibit LIPGpolypeptide activity in vitro. Once identified, an “inhibitory peptide”is then tested for its ability to inhibit the LIPG polypeptide in vivo.Inhibitory peptides will be produced recombinantly in E. coli andpurified by methods known in the art. The effect of the inhibitorypeptides will be studied in wild-type and LIPG transgenic mice byadministering the inhibitory peptide by intravenous injection. Activityof the LIPG polypeptide will be measured in plasma before and afterheparin injection (to release the enzyme from bound sites). In addition,cholesterol, VLDL, LDL and HDL cholesterol and apoA-I levels will bemonitored in animals receiving the inhibitory peptide. Finally, LDLreceptor deficient mice will be fed an atherogenic diet and administeredthe inhibitory peptide or placebo for a period of 8 weeks.Atherosclerosis will be quantitated in the aortas of the mice in orderto determine whether administration of the inhibitory peptide reducesthe progression or induces regression of atherosclerosis. Based on thesepreclinical data, additional animal models such as hamsters, rabbits orpigs will be studied for the ability of the inhibitory small molecule toraise HDL cholesterol levels, reduce VLDL and LDL cholesterol levels,and/or inhibit the progression of atherosclerosis.

Those inhibitory peptides found to have the desired properties will beadministered to patients in combination with pharmaceutically acceptablecarriers. The inhibitory peptides may be administered in a variety ofways, including oral administration and intravenous injection. Thepatients' HDL, VLDL and LDL cholesterol levels will be monitored todetermine efficacy of the inhibitory peptides and to optimize dosage andadministration protocols.

Example 20 Antisense Treatment Method

A series of antisense oligonucleotides, each complementary to about 20bases of the LIPG cDNA sequence are chemically synthesized by standardtechniques. To determine the most efficient oligonucleotide to usetherapeutically, each oligonucleotide is individually transfected intocells expressing the LIPG gene, using standard transfection protocols.

At about 24-48 hours following transfection of the oligonucleotides, theLIPG mRNA level in cells is determined by quantitative PCR, northernblot, RNAse protection, or other appropriate methods. Alternatively,LIPG expression may be monitored with specific antibodies, which can beused to screen for effective antisense oligonucleotides.Oligonucleotides which effectively reduce LIPG mRNA levels are thenformulated for in vivo delivery as therapeutics.

Antisense LIPG sequences may be delivered in a gene therapy vector, suchas adenovirus, adeno-associated virus, retrovirus, naked DNA, or othersystems discussed in the detailed description. Such fragments can beused therapeutically when delivered in gene therapy vectors. Hepaticexpression of such recombinant vectors is a preferred approach.Alternatively, synthetic antisense oligonucleotides may be formulatedfor in vivo delivery as therapeutics as described above.

Antisense oligonucleotides may be administered by the following routes:intravenous, subcutaneous, introdermal, pulmonary, oral,intraventricular, intrathecal, and topical. The route of administrationmay include direct administration to vessel walls (i.e., endotheliumand/or vascular smooth muscle). As an example, patients with low HDL-Ccould receive a dose of 0.5-2 mg/kg of an effective antisenseoligonucleotide, infused intravenously, every other day for up to 2-3weeks. As LIPG is expressed in the liver, it may be desirable to deliverantisense reagents to the portal circulation. This may be accomplishedby conjugating or complexing the oligonucleotide with a liver-targetingmoiety, such as asialoglycoprotein. Dose and timing of therapy woulddepend on efficiency of antisense delivery, as well as parameters suchas half life, specificity and toxicology of the antisenseoligonucleotide.

Increase in HDL-C can be monitored using standard clinical laboratoryprocedures. The original dosing schedule (such as that described above)is repeated as often as required to maintain HDL-C above 35 mg/dL.

Example 21 Ribozyme Treatment Method

Based on the LIPG cDNA sequence, hammerhead ribozymes which effectivelyreduce LIPG mRNA levels are prepared. These consist of two “arms” of 6-7bases each of nucleotide sequence complementary to LIPG mRNA, separatedby the catalytic moiety of the ribozyme. Examples of such hammerheadmotifs are described by Rossi et al., 1992, Aids Research and HumanRetroviruses, 8, 183. The ribozymes are expressed in eukaryotic cellsfrom an appropriate DNA vector.

The ribozymes may be administered encapsulated in liposomes, asdiscussed above.

The ribozyme/liposome composition is delivered to the liver by directinjection or by use of a catheter, infusion pump or stent. The route ofadministration may include direct administration to vessel walls (i.e.,endothelium and/or vascular smooth muscle). Patients are treated for upto 2 weeks with 5-50 mg/kg/day ribozyme in a pharmaceutically effectivecarrier. Increase in HDL-C and dosing regimen are monitored anddetermined as for antisense oligonucleotides.

Example 22 Neutralizing Antibody Treatment Method

Anti-LIPG antibodies, antibody fragments, or chimeric antibodiesconsisting of at least one LIPG-binding moiety, prepared as described inExample 12, are used to inhibit LIPG activity in vivo. The antibodiesmay be delivered as a bolus only, infused over time, or both. Typicallya dose of 0.2-0.6 mg/kg is given as bolus, followed by a 2 to 12-hourinfusion. Alternatively, multiple bolus injections are administeredevery other day, or every third of fourth day, as required to reduceLIPG and raise HDL-C. Repeat dosing is performed as determined bymeasurement of HDL-C levels. Antibodies to LIPG may also be delivered ina gene therapy vehicle to facilitate expression in vivo. The level ofexpression of the antibody is determined indirectly by measuring HDL-Clevels and additional vectors may be introduced as needed.

Example 23 Use of Inhibitory Molecules or Enhancer Molecules

Fragments of LIPG protein, which can inhibit LIPG activity by competingfor binding to intact LIPG, required coactivator molecules, cell surfacereceptors or binding proteins, may be delivered as therapeuticrecombinant proteins or from gene therapy vectors.

As an example, the LLGN polypeptide based on LIPG is cloned into arecombinant adenovirus as described (Tsukamoto et al., J. Clin. Invest.,100, 107-114 (1997); Tsukamoto et al., J. Lipid Res., 38, 1869-1876(1997)). The LLGN cDNA is cloned into the shuttle plasmid vectorpAdCMVLink1. After screening for the appropriate orientation byrestriction analysis, the plasmid is linearized with NheI andcotransfected into 293 cells along with adenoviral DNA digested withClaI. Cells are then overlaid with agar and incubated at 37° C. for 15days. Plaques are picked and screened by PCR; plaques positive for cDNAare subjected to a second round of plaque purification. Afterconfirmation of the presence of cDNA, the recombinant adenovirus isexpanded in 293 cells at 37° C. Cell lysates are used to infect HeLacells for confirmation of the expression of human EL by western blot ofconditioned media. The recombinant adenovirus is further expanded in 293cells and purified by cesium chloride ultracentrifugation. The purifiedviruses are stored in 10% glycerol/PBX at −80° C. The patient isinjected intravenously with the recombinant adenovirus 1×10¹¹ particles(approximately 2×10⁹ pfu).

Example 24 Methods of Increasing the Level of LIPG in a Patient byExpression of LIPG from an Expression Vector

The full length LIPG cDNA is cloned into a recombinant adenovirus(Tsukamoto et al., J. Clin. Invest., 100, 107-114 (1997); Tsukamoto etal., J. Lipid Res., 38, 1869-1876 (1997)) encoding human LIPG. Thefull-length human LIPG cDNA is cloned into the shuttle plasmid vectorpAdCMVLink1. After screening for the appropriate orientation byrestriction analysis, the plasmid is linearized with NheI andcotransfected into 293 cells along with adenoviral DNA digested withClaI. Cells are overlaid with agar and incubated at 37° C. for 15 days.Plaques are picked and screened by PCR; plaques positive for cDNA aresubjected to a second round of plaque purification. After confirmationof the presence of cDNA, the recombinant adenovirus is expanded in 293cells at 37° C. Cell lysates are used to infect HeLa cells forconfirmation of the expression of human LIPG polypeptide by western blotof conditioned media. The recombinant adenovirus (AdhEL) is furtherexpanded in 293 cells and purified by cesium chlorideultracentrifugation. The purified viruses are stored in 10% glycerol/PBXat −80° C. Patients are injected intravenously with AdhEL or Adnull1×10¹¹ particles (approximately 2×10⁹ pfu).

Example 25 Methods of Increasing the Level of LIPG Activity byAdministration of a Full-Length Wild-Type or Engineered Recombinant LIPGProtein

The wild-type LIPG protein reduces VLDL and LDL cholesterol levels andLIPG could be engineered to act specifically on VLDL and LDL cholesterolwithout having effects on HDL cholesterol. Administration of wild-typeor engineered recombinant LIPG could in certain circumstances be used asa therapy for reducing VLDL and/or LDL cholesterol levels. Wild-typeand/or engineered LIPG protein (“recombinant LIPG protein”) will beproduced recombinantly in E. coli and purified using methods known inthe art. Wild-type mice will be studied by administering the recombinantLIPG protein by intravenous injection. Activity of LIPG will be measuredin plasma. In addition, cholesterol, VLDL, LDL and HDL cholesterol andapoA-I levels will be monitored in animals receiving the recombinantLIPG protein. Finally, LDL receptor deficient mice will be fed anatherogenic diet and administered the recombinant LIPG protein orplacebo for a period of 8 weeks. Atherosclerosis will be quantitated inthe aortas of the mice in order to determine whether administration ofthe recombinant LIPG protein reduces the progression or inducesregression of atherosclerosis. Based on these preclinical data,additional animal models such as hamsters, rabbits, or pigs will bestudied for the ability of the recombinant LIPG protein to reduce VLDLand LDL cholesterol levels and/or inhibit the progression ofatherosclerosis. Those recombinant LIPG proteins found to have thedesired ability to reduce VLDL and LDL cholesterol levels and/or inhibitthe progression of atherosclerosis will be combined with apharmaceutically acceptable carrier and administered to patients. Therecombinant LIPG polypeptides may be administered in a variety of ways,including oral administration and intravenous injection.

All the references discussed herein are incorporated by reference.

One skilled in the art will readily appreciate the present invention iswell adapted to carry out the objects and obtain the ends and advantagesmentioned, as well as those inherent therein. The peptides,polynucleotides, methods, procedures and techniques described herein arepresented as representative of the preferred embodiments, and intendedto be exemplary and not intended as limitations on the scope of thepresent invention. Changes therein and other uses will occur to those ofskill in the art which are encompassed within the spirit of theinvention or defined by the scope of the appended claims.

1-65. (canceled)
 66. A composition for modulating the activity of LIPGcomprising an enhancer or inhibitor of LIPG expression.
 67. Acomposition for modulating the activity of LIPG comprising an enhanceror inhibitor of LIPG enzymatic activity.